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Response To Stress By The Tumor Microenvironment 
Abstract 
Fibroblasts are typically quiescent and tumor suppressive in adult mammals but secrete factors upon 
activation in benign and malignant diseases such as wound healing and tumor growth1. As residents of 
the tumor microenvironment (TME), fibroblasts are subjected to the same stresses that tumor cells 
experience including nutrient deprivation that activates the integrated stress response (ISR) pathway. This 
eventually leads to either apoptosis due to intense or prolonged stress or autophagy to promote cellular 
survival in the absence of essential nutrients2–5. Studies have shown that nutrient deprivation also 
activates the tumor suppressor p53 in fibroblasts. However, little is known about the role of other tumor 
suppressors such as the INK4a locus of the CDKN2A gene, the second most commonly mutated tumor 
suppressor gene in human cancers6–8. The INK4a locus encodes two tumor suppressor genes including 
the p19 Alternative reading frame (p19Arf) that activates p53 by sequestering the ubiquitin ligase MDM2. 
While P19Arf regulation has been well characterized in cancer cells, its role in the TME has not been 
investigated. Endothelial cells in the TME are also subjected to stress such as shear stress that is altered 
upon changes in blood flow as a consequence of tumor vascularization as well as activities such as 
aerobic exercise. Exercise is commonly prescribed to cancer patients to enhance quality of life however, 
the effect of exercise during chemotherapy has not been extensively investigated. My work shows that 
the growth of transplanted tumor cells in the flank of mice is significantly upregulated in p19Arf-/- mice as 
compared to wild-type littermate controls indicating a role for P19Arf in the TME. My studies show that 
primary murine adult lung fibroblasts (ALFs) induce P19Arf expression upon nutrient deprivation and that 
prolonged leucine deprivation triggers apoptosis in wild-type ALFs. However, p19Arf-/- ALFs demonstrate 
enhanced proliferation, migration and survival in response to long-term leucine deprivation due in part to 
upregulation of the ISR pathway and increased autophagic flux. My data also suggests that loss of p19Arf 
in fibroblasts promotes survival during nutrient deprivation through increased proliferation and autophagy. 
My studies investigating the effect of acute aerobic exercise on endothelial cell activation and 
subsequent tumor vascular normalization show that a single round of acute exercise enhances 
chemotherapeutic efficacy when administered after exercise in melanoma xenograft tumor models 
independent of tumor vascular normalization. My data suggests that acute exercise may provide an 
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RESPONSE TO STRESS BY THE TUMOR MICROENVIRONMENT 
Kerry Roby 
Sandra Ryeom 
Fibroblasts are typically quiescent and tumor suppressive in adult mammals but secrete 
factors upon activation in benign and malignant diseases such as wound healing and 
tumor growth1. As residents of the tumor microenvironment (TME), fibroblasts are 
subjected to the same stresses that tumor cells experience including nutrient deprivation 
that activates the integrated stress response (ISR) pathway. This eventually leads to either 
apoptosis due to intense or prolonged stress or autophagy to promote cellular survival in 
the absence of essential nutrients2–5. Studies have shown that nutrient deprivation also 
activates the tumor suppressor p53 in fibroblasts. However, little is known about the role 
of other tumor suppressors such as the INK4a locus of the CDKN2A gene, the second 
most commonly mutated tumor suppressor gene in human cancers6–8. The INK4a locus 
encodes two tumor suppressor genes including the p19 Alternative reading frame (p19Arf) 
that activates p53 by sequestering the ubiquitin ligase MDM2. While P19Arf regulation has 
been well characterized in cancer cells, its role in the TME has not been investigated. 
Endothelial cells in the TME are also subjected to stress such as shear stress that is 
altered upon changes in blood flow as a consequence of tumor vascularization as well as 
activities such as aerobic exercise. Exercise is commonly prescribed to cancer patients to 
enhance quality of life however, the effect of exercise during chemotherapy has not been 
extensively investigated. My work shows that the growth of transplanted tumor cells in the 




littermate controls indicating a role for P19Arf in the TME. My studies show that primary 
murine adult lung fibroblasts (ALFs) induce P19Arf expression upon nutrient deprivation 
and that prolonged leucine deprivation triggers apoptosis in wild-type ALFs. However, 
p19Arf-/- ALFs demonstrate enhanced proliferation, migration and survival in response to 
long-term leucine deprivation due in part to upregulation of the ISR pathway and increased 
autophagic flux. My data also suggests that loss of p19Arf in fibroblasts promotes survival 
during nutrient deprivation through increased proliferation and autophagy. My studies 
investigating the effect of acute aerobic exercise on endothelial cell activation and 
subsequent tumor vascular normalization show that a single round of acute exercise 
enhances chemotherapeutic efficacy when administered after exercise in melanoma 
xenograft tumor models independent of tumor vascular normalization. My data suggests 
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CHAPTER 1: Introduction 
 
Over 90% of all cancer related-deaths are due to metastatic progression9. Initial 
studies investigating cancer treatment focused solely on the primary tumor, but in 1889 
Dr. Stephen Paget introduced a concept that shifted our understanding of cancer 
progression. Paget’s theory of metastasis suggested that upon entering the blood 
stream, cancer cells (seeds) are selective in terms of the organ site where they will 
metastasize and grow. He proposed that the landing site or colonization of circulating 
metastatic cancer cells is regulated by the conditions in a distal organs 
microenvironment (soil)10,11. The tumor microenvironment (TME) is the local area 
surrounding the tumor cells consisting of different cellular populations that include 
immune cells, endothelial cells, and fibroblasts as well as extracellular matrix proteins 
(Figure 1.1). 
2 
Cellular Populations in the Tumor Microenvironment 
Immune Cells 
In response to antigens expressed on the surface of tumor cells, immune cells, 
such as CD8+ cytotoxic T lymphocytes, are primed and activated to induce cancer cell 
death via the release of cytotoxic granules or Fas Ligand-mediated apoptosis12. 
Activated T-cells proliferate rapidly to exert effector functions that require the 
consumption of large amounts of nutrients and resources that are scarce in the TME, 
such as amino acids. T-cells accomplish this by increasing the expression of amino acid 
transporters on their cell surface that are required for different processes such as T-cell 
Figure 1.1: Cartoon depiction of the cellular populations in the tumor microenvironment. 
The tumor microenvironment characteristically possesses aberrant tumor vasculature with 
heterogeneous population of cells surrounding cancer cells, that include endothelial cells, 
fibroblasts, and immune cells. 
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activation, homeostasis, differentiation, and memory13. One particular amino acid 
transporters is the L-type amino acid transporter 1 (LAT1) which is responsible for 
transporting neutral amino acids including leucine, isoleucine, and valine into the cell14. 
LAT1 has been shown to be highly expressed on cancer cells but expressed at low 
levels on normal cells with the exception of activated T-cells. In activated human T-cells, 
upregulation of LAT1 expression correlated with high cytotoxic cytokine production that 
was abrogated when LAT1 was specifically targeted and deleted or inhibited using a 
LAT1 selective inhibitor, JPH20315. While immune cells play vital roles in the 
suppression of tumor growth through inducing apoptosis of cancer cells, a subset of 
immune cells also promote tumorigenesis by creating an immunosuppressive TME 
preventing the function of anti-tumor immune cell populations. For instance, 
macrophages are part of the innate immune response that are activated and skewed 
towards either a classical (M1) or alternative (M2) phenotype. M1 macrophages function 
in an anti-tumor manner and are activated in response to IFN-g releasing pro-
inflammatory cytokines, including TNF-a, and express MHC-I & II antigens to facilitate 
phagocytosis of tumor cells16. In contrast, M2 macrophages are activated in response to 
IL-4/IL-13 to inhibit the pro-inflammatory response by M1 macrophages and inhibit 
cytotoxic T-cells through direct cell-cell  interaction.16,17 In cancer, tumor associated 
macrophages (TAMs) comprise as much as 50% of the tumor mass and typically 
possess a M2 expression pattern. Although macrophages in the TME are often 
described as having a distinct M1 or M2 phenotype, data suggests that macrophage 
phenotypes exist on a continuum of macrophage polarization between M1 and M2 such 
that the TME pivots tumor killing M1 macrophages towards tumor-promoting M2 
macrophage phenotypes18.  M2 macrophages of the TME promote tumor progression 
4 
 
through suppression of pro-inflammatory cytokines such as IL-12 and IL-23, and the 
increased expression of the catabolic arginine enzyme, arginase-116. Arginase-1 
metabolizes arginine into ornithine and polyamines, precursors necessary for cellular 
proliferation thus promoting tumor progression19. In efforts to enhance effector T-cell 
function in cancer, immune checkpoint blockade therapies targeting the immune 
checkpoint inhibitors, CTLA-4 and PD-1-PD-L1 are currently being utilized in the 
treatment of many different cancer types with varying results from complete cure to lack 
of efficacy in tumors such as melanoma20 and prostate cancer21, respectively.   
 
Endothelial cells  
The endothelial cell population in the TME play key roles in cancer progression. 
Endothelial cells form new blood vessels during development and during tumor growth. 
During development, vasculogenesis is the process of establishing new vasculature 
during embryogenesis from bone marrow endothelial progenitor cells. In comparison, 
during tumorigenesis, endothelial cells also form new blood vessels, but this process is 
called neo-angiogenesis and is the generation of new blood vessels from existing 
vessels to support tumor expansion. In response to signals from the tumor, such as 
increased production of vascular endothelial growth factor (VEGF), endothelial cells 
become activated, alter their secretome, proliferate, migrate and form vessels. 
Endothelial cell activation leads to the degradation of basement membrane, 
endothelial cell migration, proliferation, and differentiation leading to the formation of 
blood vessels that contribute to promote tumor progression and metastasis22. Because 
of the reliance of endothelial cells on VEGF for activation and angiogenesis, anti-
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VEGF/VEGF receptor therapies have been a long-standing area of investigation and the 
target of drug development to prevent tumor angiogenesis with the hopes that 
preventing blood supply to tumor cells would inhibit cancer progression. The excitement 
in targeting angiogenesis was in part due to the notion that this could be a universal 
approach to treating cancer since it was assumed that endothelial cells were the same 
regardless of the organ environment they resided.  Thus, the ability to attenuate the 
expansion of blood vessels would ‘starve’ any tumor, regardless of their organ site.  
While effective in inhibiting tumor growth in vitro and in mouse models, the use of 
anti-angiogenic therapy showed limited efficacy in clinical trials. The human VEGF 
antibody, Bevacizumab, was shown to be effective in a limited number of cancer types 
with improved overall and progression-free survival in colorectal, lung, kidney, and 
glioblastoma when used in combination with other chemotherapies. Initially, 
Bevacizumab was thought to show efficacy in treating metastatic disease as well. 
However, side effects such as hypertension, thromboembolic events, ventricular 
dysfunction, myocardial infarction, gastrointestinal perforation, and proteinuria23 showed 
that the toxicity of Bevacizumab in combination with chemotherapy did not improve 
overall survival. Some possible explanations for the lack of efficacy of anti-angiogenic 
therapies include the assumptions that endothelial cells in the TME were genetically 
stable and reliant solely upon VEGF for their activation. Further investigation into tumor 
associated-endothelial cells identified that they may not be genetically stable with one 
study indicating that tumor associated endothelial cells are aneuploid, harboring an 
abnormal number of chromosomes24. Studies have also characterized the abnormal 
function and structure of tumor blood vessels. While normal blood vessels are highly 
organized and efficient in the circulation of blood, nutrients, and drugs throughout the 
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body, tumor blood vessels are inefficient conduits possessing disorganized, leaky 
vasculature and blind-ending sprouts that prevent proper perfusion of the tumor reducing 
effective drug delivery25.  Studies have also demonstrated that some cancers become 
resistant to anti-VEGF therapy resulting in continued tumor angiogenesis and tumor 
progression26. Due to the significant level of circulating VEGF within the TME, 
Bevacizumab treatment at doses that limit adverse side effects is insufficient to 
effectively sequester circulating tumor-derived VEGF; this potentially allows for 
endothelial cells to continue functioning using alternative growth factors along with low 
levels of VEGF.  
Aberrant vasculature is a common characteristic of the TME contributing to the 
inefficacy of anti-angiogenic therapy as well as chemotherapy. Due to the constant 
demand for nutrients in the TME and the increased VEGF secreted by tumor cells, tumor 
blood vessels are generated rapidly and are immature resulting in an abnormal 
vasculature. Normal blood vasculature consists of a mature, tightly organized endothelial 
cell layer that is surrounded by basement membrane and pericytes such as smooth 
muscle cells (Figure 1.2).  In contrast, tumor vessels possess abnormal vasculature due 
in part to the rapid proliferation of the endothelial cell population resulting in gaps in the 
endothelial cell barrier making this newly generated vasculature leaky and fenestrated 




Leaky vessels also prevent even distribution of basement membrane and inefficient 
pericyte coverage making these vessels stunted in their development with collapsed 
lumens28. Due to the poorly constructed blood vessel network in tumors, the distribution 
of chemotherapy or other targeted therapies for cancer treatment is relatively inefficient. 
Dr. Rakesh Jain first described the concept of tumor vascular normalization through 
sequestering VEGF and other pro-angiogenic proteins permitting maturation of the 
vasculature by restoring the balance between pro- and anti-angiogenic proteins. The 
decrease in pro-angiogenic protein such as VEGF suppresses endothelial cell 
proliferation and migration allowing increased adhesion between endothelial cells and 
pericyte coverage of blood vessels. It was proposed that tumor vascular normalization 
leads to longer, more functional vessels with adequate lumens increasing blood flow and  
providing a window to improve chemotherapeutic efficacy. In support of the concept of 
tumor vascular normalization, Dickson, et al, showed that treatment of a mouse model of 
neuroblastoma with a single dose of Avastin, a murine anti-VEGF sequestering antibody, 
Figure 1.2: Cartoon of normal and tumor associated blood vasculature. Normal blood 
vessels contain an endothelial cell layer with tight junctions and evenly distributed 
extracellular matrix that is encased within a pericyte covering. In contrast, tumor blood 
vessels are immature as they lack pericyte coverage, are highly disorganized and lack tight 
junctions leading to a leaky endothelial cell layer. This leads to sporadic sprouting with 
collapsed lumens and unevenly deposited extracellular matrix. 
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increased vessel maturation, drug penetrance, and trended towards a reduction in tumor 
growth when used in combination with topotecan29. In addition, Winkler, et al, showed 
that treatment with the VEGF2R antibody DC101, was effective in normalizing the tumor 
vasculature of human glioblastoma xenografts resulting in a decrease in hypoxic 
regions, increased pericyte coverage, and reduced basement membrane thickness 
through increased degradation by matrix metalloproteinases30–33. While many studies 
have investigated the use of anti-angiogenic therapies to promote tumor vasculature 
normalization, the limited window and the adverse side effects indicate a need for other 
approaches to normalize tumor vessels. Chapter 4 will discuss my work investigating 




Another major cellular population in the TME is the fibroblast. Fibroblasts are 
typically quiescent cells that reside in the interstitial spaces of tissues. They become 
activated in response to a variety of stimuli such as injury or activating signals such as 
transforming growth factor-b (TGF-b)34. In response to injury such as a wound in the 
skin, fibroblasts enter a reversible activation state where they become contractile and 
migratory, and gain expression of markers including vimentin, and alpha smooth muscle 
actin (a-SMA). Activated fibroblasts deposit extracellular matrix (ECM) components, 





production of matrix metalloproteinases (MMPs) to degrade existing matrix, until the 
wound is closed and has healed1. Tumors are often referred to as a wound that is unable 
to heal35, due in part to the similarity between activated fibroblasts in wounds and the 
activated state of fibroblasts in cancer (Figure 1.3).  
Cancer associated fibroblasts (CAFs) have a similar phenotype and function as 
normal fibroblasts but are considered to be constitutively activated. As a result of 
increased and persistent production of TGF-b and other fibroblast activating factors by 
cancer cells in the TME, CAFs are unable to return to a quiescent/resting state resulting 
in their increased contractility, proliferation, migration, altered secretome and ECM 
remodeling. CAFs remodel the ECM at higher rates as compared to activated normal 
fibroblasts through the production of collagens as well as increased secretion of MMPs 
that degrade and reorganize the ECM. CAFs remodel the ECM in a pro-tumorigenic 
manner by secreting factors including hepatocyte growth factor (HGF), fibroblast growth 
factor (FGF), and TGF-b which promote migration, invasion, and metastasis of cancer 
Figure 1.3: Cartoon of stages of fibroblast activation. Fibroblasts are typically quiescent 
and dormant within tissues. They become activated in response to stimuli, such as wound 
healing, to remodel the extracellular matrix through the deposition of type I and IV collagens 




cells36. Gaggiolli et al.,37showed that squamous carcinoma cells were able to migrate 
through a matrix layer in a fibroblast dependent manner albeit through direct cell-cell 
contact. 
The identification of a specific CAF marker has been long sought after as both 
normal fibroblasts and CAFs express a-SMA and vimentin. Studies now agree that the 
cell surface receptor, fibroblast activation protein (FAP) may be the best marker for 
CAFs as FAP expression is primarily upregulated on CAFs. FAP is a member of the 
dipeptidyl peptidase (DPP) family of enzymes, sharing 50% homology with its closest 
member, DPPIV.38 FAP 
monomers become activated 
through the formation of 
homodimers or heterodimers 
with other FAP monomers and 
DPPIV monomers, 
respectively38  (Figure 1.4). FAP 
remodels  components of the 
ECM in response to injury, and 
has been shown to increase the 
expression of a-SMA, collagen 
type I, and fibronectin39. FAP expression is typically low in normal tissue, but is 
upregulated on CAFs in many different tumor types including pancreatic cancer, breast 
cancer and lung cancer; it’s high expression is also associated with poor prognosis of 
cancer patients40.  
Figure 1.4: Cartoon of Fibroblast Activation 
Protein (FAP) activation on the cell surface. FAP 
expression is upregulated on the surface of cancer 
associated fibroblasts (CAFs). FAP  monomers 
(green) are inactive but are able to become active 
through dimerization with other FAP monomers or 
dipeptidyl peptidase (DPP) IV monomers. 
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With the identification of FAP as a relatively specific CAF marker, this has 
presented a therapeutic option to target fibroblasts in the TME for cancer treatment. The 
targeting of FAP expressing cells in an effort to suppress tumor growth has become an 
area of active investigation. Genetic ablation or pharmaceutical inhibition of FAP in vivo 
inhibited colon cancer tumor growth41 and lung cancer in mouse models42; 
pharmacological inhibition of FAP with the GluBoroPro dipeptide, PT630, inhibits the 
enzymatic functions of FAP and DPPIV and efficiently inhibited tumor growth in these 
models. FAP’s expression within the tumor stroma has also led to the development of 
chimeric antigen receptor (CAR) – T cells that are designed to target FAP+ cells. The use 
of FAP specific CAR-T cells inhibited mesothelioma and lung cancer growth and 
increased cytotoxicity within tumors in addition to ablating FAP+ cardiac fibroblasts in a 
mouse model of cardiac fibrosis43,44.  
 
Stress and the Tumor Microenvironment 
As a result of the exponential proliferation rate of cancer cells, they sequester 
resources for themselves triggering various stressors in the TME including hypoxia, 
acidosis, and nutrient or amino acid deprivation. Due to the disorganized and inefficient 
vasculature associated with a rapidly developing tumor, a common stress is the 
restriction of oxygen or hypoxia. In response to hypoxia, stabilization of the transcription 
factors hypoxia inducible factors (HIFs)45 occurs in both cancer and normal cells. The 
oxygen-sensing subunit of HIFs, HIF-1a, dimerizes with HIF-1b to induce the 
transcription of genes allowing cells to alter their metabolism into an aerobic glycolytic 
state to continue the production of energy during low oxygen conditions46. The HIF-1a 
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subunit is kept at low levels during normoxia by its ubiquitination and proteasomal 
degradation by the von Hippel-Lindau protein (pVHL). Specifically, HIF-1a becomes 
hydroxylated by the oxygen-dependent proly-hydroxylase domain-containing proteins 
(PHDs) at proline sites facilitating binding by pVHL45,47. HIF-1a expression is 
upregulated in cancers and in the TME inducing changes in resident cellular populations 
to support tumor progression, such as the transformation of fibroblasts to CAFs45. As a 
consequence of increased hypoxia, cells of the TME cannot utilize oxidative 
phosphorylation to produce energy from glucose. This results in the utilization of 
anaerobic glycolysis which is an alternative method for cells to produce energy in 
hypoxic environments, albeit at lower levels. Interestingly, cancer cells were discovered 
to convert glucose into energy in a less efficient manner regardless of oxygen status, 
which is termed the Warburg effect48. As a result of inefficient perfusion of the TME, both 
anaerobic glycolysis and the Warburg effect expel high amounts of lactic acid into the 
surrounding TME resulting in an acidic microenvironment49. Acidosis of the TME results 
in metabolic reprogramming of cancer cells and CAFs alike to aid in tumor progression 
and chemoresistance50. For instance, Hexokinase 2 (HK2) has been shown to be 
upregulated in CAFs resulting in increased cell cycle progression and suppressed p27 
expression51. Despite the acidic and hypoxic conditions of the TME, cancer cells 
continue to rapidly proliferate sequestering nutrients resulting in nutrient deprivation 
within the TME. Nutrient deprivation is a hallmark of cancer that forces cancer cells to 
become scavengers to acquire the nutrients necessary to maintain their proliferation in a 
stressful environment. Avagliano et al. suggest that CAFs in the TME become forced to 
use the Warburg effect to produce high energy metabolites that cancer cells utilize to 
maintain their proliferation52. In addition to metabolites, such as pyruvate and ketone 
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bodies, amino acids are a viable resource that are scarce and preferentially taken up by 
rapidly proliferating cancer cells. Attempts to target enhanced amino acid consumption 
has resulted in varying effects. While glutamine overconsumption is a common trait of 
the TME, targeting the essential amino acid, leucine, can induce apoptosis of human 
breast cancer cell lines53. To counter the stressful microenvironment, the integrated 
stress response (ISR) pathway is an evolutionarily conserved pathway that evolved so 
that cells could survive the effect of stressors ranging from viral infection, misfolded 
proteins, acidosis and nutrient deprivation.  
The Integrated Stress 
Response Pathway 
The core of the 
ISR pathway consists of 
a class of kinases that 
are activated exclusively 
in response to specific 
stimuli (Figure 1.5). The 
kinases heme-regulated 
inhibitor eIF2a kinase 
(HRI), double-stranded 
RNA-dependent protein 
kinase (PKR), PKR-like 
ER Kinase (PERK), and 
general control non-
depressible protein 2 (GCN2) all  converge to phosphorylate the eukaryotic initiation 
 Figure 1.5: Schematic of the Integrated Stress Response   
 Pathways.  Kinases are activated in response to the indicated  
 stimuli to phosphorylate the eukaryotic initiation factor 2 alpha  
 (eIF2a) subunit resulting in 1) the inhibition of global  
 translation and 2) translation of specific proteins with conserved   
 upstream open reading  frames such as activating transcription  
 factor 4 (ATF4). ATF4 transcribes genes generating non-  
 essential amino acids or promoting autophagy. Prolonged stress 
 increases expression of the apoptosis inducing C/EBMP  
 homologous\protein (CHOP).General non-depressible protein 2  
 (GCN2), heme-regulated inhibitor (HRI), RNA-dependent   
 protein kinase (PKR), and PKR-like ER (PERK). Adapted  from  
 Pakos-Zebrucka, et al,EMBO Reports 2016.  
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factor 2 -alpha (p-eIF2a) subunit. This results in the halting of general protein translation 
with the exception of genes including activating transcription factor 4 (ATF4). ATF4 
transcribes genes that initially promote cell survival under stress including autophagy 
related gene 5 (ATG5) to promote autophagy. However, when the stress is prolonged, 
ATF4  transactivates genes that promote cell death including pro-apoptotic genes such 
as C/EBMP homologous protein (CHOP). 
The HRI arm of the pathway is activated in response to heme deprivation. In 
normal conditions, heme binds both the N-terminus and kinase binding domain to keep 
HRI inactive, but when heme is deprived HRI dimerizes to auto-phosphorylate itself to 
become activate54. While the other arms of the ISR are broadly distributed between 
tissues, HRI is found within erythroid cells and is required for erythrocyte differentiation 
and regulating globin production55. In cancer, HRI can be both anti-tumor or tumor 
promoting as it has been to shown to be regulated by the ternary complex inhibitor, N,N′-
diarylureas, to induce the phosphorylation of eIF2a and sequential increase in CHOP to 
induce prostate cancer cell death and inhibit human prostate tumor growth56. In contrast, 
its ablation in bortezomib resistant human prostate cancer cells sensitizes them and 
induces cell death57. 
The PKR arm of the pathway is activated in response to double stranded RNA 
(dsRNA) that is typically associated with viral infection. When activated, PKR dimerizes 
and auto-phosphorylates itself at threonine 446 to subsequently phosphorylate eIF2a. In 
infections such as Hepatitis virus C (HCV), PKR levels are upregulated in response to 
dsRNA as a result of the increased viral proliferation. Due to chronic infection, HCV 
progresses and develops into liver cirrhosis and eventually hepatocellular carcinoma 
(HCC) although the molecular mechanisms underlying this progression are not well 
15 
 
characterized58. Hiasa et al, showed that PKR expression was increased in HCV-related 
tumor regions when compared to non-tumor areas in patient samples suggesting a 
requirement for PKR in HCV-related HCC59. 
In response to ER stress, the unfolded protein response pathway becomes 
activated involving the activation of inositol-requiring enzyme (IRE-1), ATF-6a, and the 
ISR kinase, PERK. ER stress results from the accumulation of misfolded proteins that 
arise due to mutations, oxidative stress, heat-shock, or dysregulated calcium flux. These 
misfolded proteins allow for the PERK regulator, glucose regulated protein-78 (GRP78), 
to dissociate from and release the PERK kinase allowing it to dimerize, auto-
phosphorylate, and become activated54. In cancer, PERK and the unfolded protein 
response pathway is required for tumor cell survival in hypoxic regions of tumors. 
Rouschop et al, showed that colorectal cancer cells survive hypoxia through autophagy 
in a PERK-dependent manner; they established that colorectal tumors with PERK 
inhibition reduced hypoxic regions, reduced tumor growth, and showed increased 
sensitivity to irradiation60. The ISR shows redundancy when one arm is targeted. For 
example in a genetically engineered mouse model of sarcoma with a deletion of GCN2, 
the level of eIF2a phosphorylation was maintained in Gcn2-/- tumors due to 
compensation by PERK61.   
The final arm of the ISR pathway, GCN2, is activated in response to amino acid 
deprivation (AAD). In normal conditions, transfer ribonucleic acids (tRNA) are charged 
by the corresponding amino acid allowing GCN2 to remain inactivated. However, when 
cells are deprived of amino acids, tRNAs bind to GCN2 promoting a conformational 
change that permits dimerization, autophosphorylation, and activation of the kinase54. In 
addition to genes related to autophagy and apoptosis, GCN2-mediated activation of 
16 
 
ATF4 induces the production of enzymes that generate non-essential amino acids, such 
as asparagine, as needed by the cell. However, when the cell is deprived of essential 
amino acids, ATF4 promotes autophagy to allow for the degradation of cellular 
organelles to provide essential amino acids necessary for cell survival until the essential 
amino acid pool is repleted and the pathway is then inactivated. GCN2 is distributed 
among many tissue types and is required for cellular processes including cell 
proliferation, autophagy4, and angiogenesis62 in response to AAD. As is common in the 
TME, amino acids trigger activation of GCN2 in both normal cells and cancer cells. In 
human cancer cell lines, GCN2 expression was upregulated and shown to be required 
for production of VEGF and tumorigenesis while deletion of GCN2 reversed this 
phenotype and reduced tumor growth rates63. Because of the double-edged sword that 
the GCN2-ATF4 pathway 
presents in cancer, 
pharmacological approaches 
to either activate or inactive 
(Figure 1.6) the GCN2 
pathway depending on the 
cancer type and the target 
population has been an area 
of great interest54. Activators 
of GCN2 raise the levels of 
uncharged tRNAs through 
sequestering amino acids, 
such as asparagine by 
asparaginase, that subsequently bind and activate GCN2. Inhibitors of GCN2 function to 
Figure 1.6: Schematic of GCN2 pathway and 
pharmacological activators and inhibitors of the 
GCN2 kinase.. Pharmacological approaches have been 
developed to induce the activation or inhibition of the 
GCN2 kinase to be used in combination with other 




inhibit the phosphorylation of eIF2a in response to GCN2 activating stimuli, but their 
mechanism of action is not specific to GNC264.  
       The majority of work on the ISR has investigated its function in cancer cells, with 
few studies investigating the role of the ISR in other cellular populations of the TME. The 
GCN2/ATF4 pathway has been shown to be required for endothelial cell activation and 
contribute to tumor progression. In response to AAD, GCN2 activation correlates with 
increased VEGF secretion by tumor cells while interruption of the pathway significantly 
reduced VEGF levels and the number of blood vessels in tumors63. Endothelial cells 
have also been found to secrete higher levels of VEGF in vitro and increased tube 
formation in a GCN2-dependent manner when deprived of the amino acids methionine 
and cysteine in the context of hypoxia62.  GCN2 has also been shown to be critical in the 
immune populations of the TME. In a glioblastoma model, GCN2 was found to be critical 
for tumor infiltration by cytotoxic T-cells and was also shown to be pivotal for their 
survival during tryptophan deprivation.65  The ISR pathway is activated in response to 
stress stimuli in fibroblasts just as in many other eukaryotic cells. Most studies have 
focused on the role of the ISR in mouse embryonic fibroblasts (MEFs), while the role of 
the ISR in adult stromal cells of the TME has not yet been extensively investigated.  
 In summary, the TME is composed of various cell types that each contribute 
towards tumor progression both in concert and independent of other cellular populations. 
Cells in the TME have the ability to function as both pro- and anti-tumor populations thus 
it is important to understand the signaling pathways regulating these opposing actions.  
For example, the immune cell population with its surveillance ability to destroy foreign 
cells, also exhibits tumor promoting actions through their exhaustion, lack of efficacy, 
and production of factors that alter other immune populations towards a pro-tumor 
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phenotype. Endothelial cells are also subject to changes within the TME as their rapid 
expansion in response to increased production of growth factors from cancer cells 
prevents the development of fully functioning or mature blood vessels resulting in 
inefficient vasculature. Cancer associated fibroblasts, abundant throughout the TME, are 
known to promote tumor growth in part due to their increase in FAP expression which 
results in fibroblast activation and the production and remodeling of ECM proteins that 
promote tumor growth, migration and metastasis.  While the stresses of the TME are 
experienced by both tumor cells and the surrounding “normal” cells, the utilization of the 
ISR pathway promotes cell survival and is an attractive therapeutic target. Thus, it is of 
great interest to understand the role of the ISR in cells in the TME and in fibroblasts.   
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CHAPTER 2: Tumor Suppressors and the Integrated Stress Response 
 
Introduction 
In response to amino acid deprivation (AAD), previous studies on mouse 
embryonic  fibroblasts (MEFs) have shown that MEFs activate the Integrated Stress 
Response (ISR) pathway to cope with the lack of nutrients until the stress is alleviated. 
Tumor suppressors such as the most commonly mutated tumor suppressor, p53, have 
been well studied for their role in cancer cells but less is known about their role in cells in 
the tumor microenvironment (TME) 66,67. Wild-type (WT) p53 typically inhibits cancer 
progression through a number of different mechanisms including cell cycle arrest, 
induction of apoptosis and senescence.  However, mutant p53 can be pro-tumorigenic 
through functions that include regulating cancer cell metabolism with gain of function 
mutant p53 promoting glycolysis and lipid synthesis and tumor growth68. WT p53 has 
also been shown to have pro-tumor ability in cancer cells in response to AAD. Cancer 
cells with WT p53 when subjected to AAD undergo cell cycle arrest to promote their 
survival through the upregulation of the p53-target gene p21; this upregulation and 
overall cell survival was lost when p53 was ablated in these cells69,70.  Interestingly, 
upregulation of p21 in this context coincided with activation of the ISR as evidenced 
through phosphorylation of eIF2a and increased transcription of genes associated with 
the AAD response, including CHOP, which was reduced when p53 was mutated70. While 
these studies have primarily investigated p53 and its effects in cancer cells, p53’s role in 




Genetic screening of CAFs revealed that although somatic mutations of p53 in 
cancer models were rare, the potential silencing of genes by epigenetic changes in the 
TME cannot be ruled out 71,72. To this end, the silencing of p53 in CAFs has been 
investigated in tumor models. The effect of stromal cell-derived p53 on tumor growth has 
been investigated in pancreatic and carcinoma models. These studies revealed an 
increase in tumor growth when normal fibroblasts were mixed with cancer cells that was 
enhanced when p53 was deleted or mutated to mimic potential epigenetic silencing73,74. 
Studies show that the rate of tumor growth in flank tumor models was significantly faster 
when tumor cells were co-injected with normal fibroblasts and tumor growth was further 
enhanced when normal p53 was deleted, mutated or altered epigenetically. However, 
this effect was abrogated when p5374 or stromal cell derived factor -1 (SDF-1)73 were 
targeted in fibroblasts. These findings suggest that p53 in the stroma affects tumor 
growth but the effect of p53 in stromal cells in the TME in response to stress and 
activation of the ISR, has had limited investigation. In response to leucine deprivation, 
MEFs with an inactive p53 mutant still showed induction of a p21 variant in a GCN2-
dependent manner that was utilized by cells to survive the stress of AAD75. The 
depletion of p53 and its homologs, p63 and p73, did not prevent the upregulation of p21 
suggesting that p53 is not required for p21 induction in MEFs under these conditions. 
One potential explanation could be the ability of p53 homologs to act on the promoter 
regions of p53 target genes. It has been previously shown that the p63 isoform is able to 
bind the promoter region of p21 in human epidermal keratinocytes at different stages of 
differentiation76. As these studies have provided a potential link between the ISR, cell 
cycle arrest and p53, my studies have focused on investigating the effects of other tumor 
suppressors on the ISR pathway in response to stress of the TME and particularly the 
fibroblast population.  
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 Another tumor suppressor of interest is the P14 alternate reading frame 
(P14ARF) tumor suppressor, or the mouse homolog, p19Arf.  P14ARF,  the second 
most commonly mutated tumor suppressor in human cancers, is encoded in the 
CDKN2A gene67.  The role of P19Arf as a regulator of p53 activation has been well 
characterized in vivo and in vitro. In normal conditions, p53 is kept at low levels as it is 
targeted for lysosomal degradation via the E3 ubiquitin-protein ligase mouse double 
minute 2 homolog (MDM2). However when p53 activation is required in response to a 
range of cellular stresses including oncogenic stress77–79, ultra-violet  or gamma 
irradiation80, or hypoxia81, p19Arf expression is upregulated and activated, which results 
in the binding and sequestering of MDM2, translocating it to the nucleolus permitting the 
stabilization and functional activation of p53 (Figure 2.1)67,82. While this narrative 
presents p19Arf as a tumor suppressor only in a p53-dependent context, it has also 
been shown to function in a p53- independent manner. Mice with triple knock-out of 
p19Arf, p53 and Mdm2 develop multiple tumors at a frequency greater than that 
observed in mice lacking both p53 and Mdm2 or p53 alone. This data demonstrates that 
Figure 2.1: p19Arf -p53 canonical pathway. Under normal conditions, p53 activity is tightly 
regulated and targeted for degradation by the E3 ubiquitin ligase, MDM2. In response to 
cellular insults that require p53 activation, the p19Arf tumor suppressor sequesters and 
relocates MDM2 to the nucleus permitting p53 activation and function. 
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p19Arf  can act independently of the Mdm2-p53 axis in tumor suppression playing roles 
in cell cycle arrest and senescence in tumor cells77.   
P19Arf has been shown to induce cellular responses independent of p53 in 
response to oncogenic stimuli including anti-tumorigenic functions such as apoptosis, 
cell cycle arrest, and senescence. P19Arf can also induce these functions in normal 
MEFs. Weber et al., showed that when p19Arf was reintroduced into MEFs lacking p53, 
MDM2, and p19Arf, these cells displayed an ability to induce cell cycle arrest that was 
independent of the p53 target gene p2183. p14ARF has also been shown to induce cell 
death independent of p53 in human cancer cells. When P14ARF was transfected into 
p53-deficient human carcinoma cells, not only was there a reduction in viable cell 
number and an increase in apoptosis markers in vitro, but this was also recapitulated in 
vivo as harvested tumors revealed a reduction in proliferating cells and an increase in 
cleaved caspase-384,85. While apoptosis and cell cycle arrest are critical for tumor 
suppression, senescence is another cellular response that is associated with reduced 
tumor progression. The p19Arf  tumor suppressor is required to induce senescence in 
response to stress as it works in concert with the tumor suppressors Ink4a or p1685–87. In 
addition, p19Arf can also induce autophagy as another cell survival mechanism that has 
been viewed as double-edged sword in cancer for its ability to not only induce apoptosis 
as a tumor suppressive response but also its utilization by cancer cells to maintain 
sufficient nutrients for tumor progression in certain models88. Previous studies have 
shown that a small mitochondrial isoform of p19Arf (smARF) induces autophagy and 
apoptosis in a p53-dependent manner in both fibroblasts and cancer cells85,89. It has also 
been shown to promote tumor progression by promoting autophagy during nutrient 
deprivation in lymphomas85,90. While these studies have shown the involvement of 
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p19Arf in cellular responses, limited investigation has connected the ISR and the p19Arf 
tumor suppressor. One study showed the ability of ATF4 to suppress p19Arf allowing 
transformed cells to maintain plasticity and colony formation ability, that was lost when 
Atf4 was deleted7. Due to the gap in knowledge regarding the link between p19Arf and 
the ISR, my work has been investigating the role of p19Arf in stromal cells and its effect 
on the ISR in response to stress in the TME. 
As the loss of p19Arf in mouse models of cancer has been shown to promote 
tumor growth and its loss in MEFs leads to immortalization, I hypothesized that the loss 
of p19Arf in the TME enhances tumor growth through increased activation of fibroblasts. 
My data demonstrates that in addition to increased tumor growth in a p19Arf-null mouse 
host, primary p19Arf-null fibroblasts co-injected with cancer cells showed an increased 
rate of tumor growth. My data also shows that growth of 3-dimensional (3D) tumor 
organoids or tumoroids, formed in the context of a fibroblast network was enhanced 
when co-cultured with p19Arf-null fibroblasts. My data also shows that fibroblasts 
upregulate expression of the p19Arf tumor suppressor in response to prolonged leucine 
deprivation. Our data indicate a role for p19Arf in fibroblasts to slow tumor growth in 
mice and ex vivo 3D tumoroid development, in addition to our finding that P19Arf is 
upregulated in response to prolonged leucine deprivation in primary fibroblasts. 
 
Results 
Loss of p19Arf in the microenvironment increases tumor growth 
To investigate the role of P19Arf in the TME, WT or p19Arf-/- mice were inoculated 
with syngeneic murine sarcoma (SKPY) or Lewis lung carcinoma cells (LLC) in the flank 
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and tumor growth was monitored over time. The rate of tumor growth was increased in 
p19Arf-/- mice indicating a role for P19Arf in the tumor microenvironment (Figure 2.2A). To 
assess the tumor promoting capabilities of p19Arf-/- adult lung fibroblasts (ALFs), we 
generated 3D tumoroids with WT or p19Arf-null ALFs to more closely recapitulate in vivo 
tumor growth and to specifically examine the effect of ALFs on tumor growth. WT or 
p19Arf-/- ALFs were seeded in basement membrane extract. Lewis lung carcinoma (LLC) 
cells were plated on top of the solidified basement membrane and formed 3D tumors. We 
show that LLC tumoroids with fibroblasts show an increase in tumor cell numbers as 
compared to growth of LLCs alone, and this phenotype is further enhanced when 
fibroblasts with deletion of p19Arf were utilized.  This increase in tumor cell proliferation in 
3D tumoroids was also observed with p19Arf-null fibroblasts during long-term leucine 
deprivation (Figure 2.2B). To investigate whether cancer cells within the tumoroids 
promoted fibroblast activation, tumoroids were digested into single cell suspensions and 
cells were mounted and stained for proliferation and fibroblast activation using Ki67 and 
α-smooth muscle actin (SMA), respectively. My data shows actively proliferating fibroblast 
populations within the tumoroid as evidenced by nuclear Ki67 staining and α-SMA 
expression that is increased in p19Arf -/- fibroblasts (Figure 2.2C,D,E). These data suggest 
that loss of p19Arf in fibroblasts, promotes tumor cell growth in 3D tumoroid assays and 
demonstrates cross-talk between tumor cells and fibroblasts. These data further support 







P19Arf is induced in response to amino acid deprivation and activates the Integrated 
Stress Response pathway 
P19Arf is known to be induced in response to oncogenic stress and DNA damage, 
stabilizing and activating p5367,78,79. TP53 has also been shown to be upregulated during 
AAD in breast cancer cells, but the effect of AAD on P19Arf expression and function has 
not yet been investigated91. To cope with AAD, cells activate the ISR exclusively through 
the GCN2 arm of the pathway resulting in phosphorylation of eIF2a (p-eIF2a) and nuclear 
localization of ATF454. We probed for activation of the ISR in WT and p19Arf -/- ALFs in 
response to prolonged leucine deprivation with our data showing increased p-eIF2a in WT 
fibroblasts that was even further increased in p19Arf-/- fibroblasts confirming ISR pathway 
activation in both WT and p19Arf-null fibroblasts (Figure 2.3A). Activation of the ISR 
occurs through many different stimuli. To confirm dependence on GCN2 activity in 
response to AAD, we treated cells with a GCN2 inhibitor (GCN2-IN-1)92 and probed for p-
eIF2a in response to leucine deprivation.  We show increased phosphorylation of eIF2a 
in p19Arf-/- fibroblasts, which is ablated when cells were treated with GCN2-IN-1 during 
leucine deprivation confirming increased GCN2 activation in response to the amino acid 
deprivation in p19Arf-/- ALFs (Figure 2.3B).Exposure of WT ALFs to leucine deprivation 
revealed upregulation of p19Arf expression at the mRNA and protein level after 24 hours 
Figure 2.2: Loss of p19Arf in fibroblasts promotes tumor growth. A. Graph of sarcoma 
(SKPY) and Lewis lung carcinoma (LLC) tumor volume on the indicated days. SKPY or LLC 
cells were injected into the flank of WT and p19Arf-null mice. Tumor volume was measured 
by caliper. N=7-15 mice/cohort B. Representative images of tumoroids containing LLC cells 
with either WT or p19Arf -/- fibroblasts after 5 days of co-culture in basement membrane 
extract. Bars are 250µm. Quantification of cell counts are shown in graph on right. Yellow 
arrows = fibroblast network; black arrows = tumoroid. C,D,E. Representative images of 
dissociated cells from tumoroids stained for (C) Ki67, (D) a-SMA, and (E) both Ki67 and a-




that was sustained over 3 days (Figure 2.3C,D). In addition to overall expression levels 
of p19Arf, it’s localization within the cell is also indicative of its activity93. In response to 
leucine deprivation, we show that nuclear localization of P19Arf increases when leucine 
deprivation is prolonged (Figure 2.3E). These findings suggest that p19Arf induction in 











During tumor progression, the TME plays a pivotal role in the maintenance and 
growth of the primary tumor and metastasis of cancer cells. Of the populations that 
constitute the TME, stromal cells play critical roles in promoting tumor growth and 
metastatic progression. Tumor cells are thought to activate normal cells such as 
fibroblasts, in their local microenvironment leading to remodeling of matrix and creating a 
favorable niche for tumor growth. Although fibroblasts in the TME are thought to be 
genetically stable, emerging data suggests that epigenetic regulation of gene expression 
in ‘normal’ cells in the TME may play important roles in tumorigenesis. Thus studies 
investigating how loss of tumor suppressor genes such as p53 or p19Arf affects fibroblast 
function in the TME may offer insight into the role of tumor suppressors in cancer 
associated fibroblasts (CAFs)74. In this study, we investigated the role of the second most 
Figure 2.3: Leucine deprivation (LD) induces p19Arf expression in primary murine adult 
lung fibroblasts (ALF) and activates the integrate stress response pathway. A. Western blot 
analysis of phospho-eIF2a and total eIF2a expression in wild-type (WT) and p19Arf-null 
murine ALFs during LD for the indicated days. Graph quantifies intensity of phospho-eIF2a 
expression relative to Day 0. β-Tubulin used as loading control. B. Western blot analysis  of 
phospho-eIF2 expression in WT and p19Arf-/- ALFs upon treatment with a GCN2 inhibitor 
(GCN2-IN-1; A-92 1µM in DMSO) during overnight LD. Actin used as a loading control. 
Quantification of phospho-eIF2 expression relative to total eIF2a. N=3. C. qPCR for p19Arf 
mRNA in WT or p19Arf-/- fibroblasts during LD for the indicated days. D. Western blot for 
p19Arf protein expression in WT and Arf-null fibroblasts after LD for the indicated days.  E. 
Representative immunofluorescence images for P19Arf subcellular localization on the indicated 





commonly mutated tumor suppressor, p19Arf, in adult lung fibroblasts Here we show that 
p19Arf is induced in fibroblasts in response to AAD, a common stress in the TME. While 
the p19Arf tumor suppressor has been shown to be induced in response to hypoxia and 
DNA damage, its induction in response to leucine deprivation has not yet been 
demonstrated.  
Although our work did not investigate P53-independent functions of p19Arf in 
fibroblasts, its role in senescence, ribosome biogenesis, and SUMOylation has been well 
established with p19Arf expression a commonly used marker of senescence. It has also 
been suggested that increased ribosome biogenesis is a common hallmark of cancer that 
provides a potentially actionable target for cancer treatment94. Many different types of 
autophagy have been identified including mitochondrial autophagy (mitophagy) and 
ribosomal autophagy (ribophagy). Considering p19Arf’s role in regulating ribosome 
biogenesis and autophagy, it would of interest to investigate p19Arf’s tumor suppressive 
role through ribophagy. 
A known regulator of autophagy is the mTOR pathway which primarily regulates 
cell proliferation and is dependent on the availability of nutrients. In normal conditions, the 
mTOR pathway, specifically mTOR complex I (mTORC1) regulates mRNA translation, 
protein turnover, and cellular metabolism. The mTOR pathway is manipulated in cancer, 
and components of the pathway have been shown to degrade p19Arf to promote 
proliferation in MEFs95. Further studies will investigate the effect p19Arf loss on the mTOR 
pathway and its regulation on cell processes including proliferation, metabolism, mRNA 
translation, and protein turnover.  
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The loss or mutation of the human p14Arf  tumor suppressor in cancer cells has 
been identified in numerous cancer types. However, the role of the p14Arf tumor 
suppressor in the TME has not been investigated and could offer a promising area of 
investigation to enhance existing therapies. Collectively, our data demonstrate a role for 
p19Arf in fibroblast activation and its loss promotes fibroblast survival and activation during 
nutrient deprivation leading to a pro-tumorigenic phenotype in primary lung fibroblasts and 
increased tumor growth. Further elucidation of the specific downstream targets of p19Arf 
in primary lung fibroblasts will provide insight into the link between loss of p19Arf and 
activation of autophagy during nutrient deprivation and may provide new pharmacological 
targets in the stroma. 
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CHAPTER 3: p19Arf Loss Enhances Fibroblast Survival and Function During 
Prolonged Leucine Deprivation 
 
Introduction 
We have shown in Chapter 2 that the loss of p19Arf in the tumor microenvironment 
(TME) enhances tumor growth rates in murine models. This was also recapitulated in 3D 
tumoroid colonies when primary fibroblasts are the only other cell type in the local 
environment. We also showed that the loss of p19Arf in these fibroblasts not only promotes 
tumor cell proliferation in both normal conditions and leucine deprivation (LD), but also 
increases fibroblast numbers suggesting bi-directional cross-talk between tumor cells and 
fibroblasts. We investigated the role of p19Arf in these fibroblasts and showed induction 
of p19Arf at both the mRNA and protein levels in response to prolonged LD. Increased 
P19Arf expression also coincided with activation of the ISR pathway and was further 
enhanced when p19Arf was deleted in these fibroblasts. This suggests that the loss of 
p19Arf enhances fibroblast activation and promotes their stability in response to stresses 
of the TME. To this end, we investigated the function of p19Arf in primary adult fibroblasts 
to determine the survival mechanisms utilized during long-term amino acid deprivation 
(AAD) upon p19Arf loss. Other studies have investigated the role of p19Arf in fibroblasts 
in diseases other than cancer. In aging related studies, p19Arf and p14ARF are commonly 
upregulated and required to induce senescence of late passage cells86,96. P19Arf ablation 
in cells revealed the onset of age-related pulmonary fibrosis and enhanced pulmonary 
function in mice suggesting that p19Arf plays a role in fibroblast function in benign 
disease97. Fibroblast migration has also been shown to require p19Arf as Guo et al., 
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showed a decrease in fibroblast motility when p19Arf was deleted that was rescued when 
p19Arf was reintroduced98. In addition to fibroblast motility, the ability of fibroblasts to 
invade through basement membrane is also a hallmark of cancer that is associated with 
metastasis and poor tumor prognosis99. In cancer cells, p19Arf inhibits invasion through 
basement membrane in a p53-independent manner100. While these studies have indicated 
a role for p19Arf in fibroblast function and cancer cell invasion in normal conditions, it begs 
the question of whether stress in the TME alter these functions, and the contribution of 
fibroblast-derived p19Arf. 
The role of p19Arf has been implicated in various fibroblast functions and activation 
thus I hypothesized that the increased activation of p19Arf-null fibroblasts was due in part 
to increased proliferation requiring autophagy for survival during prolonged LD. Our study 
has revealed that the increased proliferation of p19Arf-null fibroblasts observed under 
normal conditions permits increased survival in response to the deprivation of the essential 
amino acid, leucine, that is lost when proliferation of p19Arf-null fibroblasts is inhibited. 
We also show increased activation of p19Arf-null fibroblasts as observed through 
increased migratory and invasive abilities even during prolonged LD. Finally, we show a 
dependence and utilization of autophagy pathways in p19Arf-null fibroblasts that promote 
cell survival even at baseline but is further upregulated in response to prolonged LD.  
Pharmacological inhibition of autophagy attenuates the survival response of p19Arf-null 







Loss of p19Arf promotes fibroblast survival during leucine deprivation  
There is little understanding of how cells in the tumor microenvironment respond 
to chronic stress during tumorigenesis such as AAD. In response to sustained AAD over 
days, we show that WT ALFs eventually die in contrast to p19Arf-/- fibroblasts that continue 
to proliferate even during long-term LD (Figure 3.1A). The loss of p19Arf in mouse 
embryonic fibroblasts (MEFs) increases proliferation due in part to the loss of p53 function 
and loss of cell cycle checkpoints67,83. p19Arf deletion enhances ALF survival during AAD 
that is due in part to the increased proliferation of p19Arf-null ALFs relative to WT ALFs. 
EdU uptake confirms the increased proliferation of p19Arf-/- ALFs as compared to WT 
fibroblasts during long-term AAD (Figure 3.1B). To determine whether increased survival 
of p19Arf-/- ALFs was due to increased proliferation, we treated fibroblasts with mitomycin 
C to inhibit DNA synthesis (Figure 3.1C) and exposed ALFs to long-term LD. Mitomycin 
C treated ALFs exposed to AAD revealed that p19Arf-/- ALFs die during long-term leucine 
deprivation similar to WT ALFs suggesting that survival of p19Arf-null fibroblasts may be 
dependent primarily on their increased rates of proliferation (Figure 3.1C). P19Arf 
activation is necessary to induce apoptosis in a p53-dependent manner101,102. To assess 
whether deletion of p19Arf in ALFs reduced apoptosis, fibroblasts were stained with 
Annexin V after AAD. Our data show similar levels of Annexin V staining between LD WT 
and p19Arf -/- ALFs indicating apoptosis in response to AAD was unaffected by p19Arf 
status (Figure 3.1D). These data suggest that the loss of Arf enhances ALF proliferation 




Figure 3.1: Loss of p19Arf enhances fibroblast proliferation during leucine 
deprivation (LD).  A. Quantification of trypan blue negative WT or p19Arf -/-  lung 
fibroblasts on the days indicated after normal (left graph) media or LD-deprived (right 
graph) media.  Fold change is relative to Day 0 cell counts. B. Representative images of 
EdU uptake (16-hour pulse) of WT or p19Arf -/ -lung fibroblasts after LD for the 
indicated days. Bar = 50µm, n=3, * p<. C. Representative images of EdU uptake of WT 
or p19Arf -/- lung fibroblasts during LD and treatment with mitomycin C (Mito C) and 
graph of viable cell numbers. Fold change is relative to Day 0. 
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P19Arf -/- fibroblasts show increased activation during leucine deprivation 
     Fibroblast activation and migration in response to injury can be modeled in a 
scratch assay. ALFs are seeded in tissue culture dishes and grown to confluency then 
denuded with a pipet tip. We show that p19Arf-/- fibroblasts migrate more rapidly than WT 
fibroblasts covering the denuded area in the presence of LD media faster than WT 
fibroblasts (Figure 3.2A). Similarly p19Arf-/- ALFs migrated more rapidly through a 
transwell in response to serum in LD conditions further indicating that loss of p19Arf 
enhances fibroblast activation (Figure 3.2B). When cancer associated fibroblasts are 
activated, they migrate through collagen and other extracellular matrix in the tumor 
microenvironment by cleaving and reorganizing matrix. Invasion assays with ALFs through 
a collagen bed revealed increased invasion by p19Arf-/- ALFs, that was maintained during 
LD suggesting more active fibroblasts and an ability to more rapidly modify collagen 
(Figure 3.2C). In collagen remodeling, ALFs both degrade and deposit collagen providing 
an opportunity to investigate the role of p19Arf in collagen deposition by primary 
fibroblasts. Quantification of hydroxyproline serves as a surrogate for collagen production 
as hydroxyproline is a major component of collagen. Utilizing supernatant collected from 
fibroblasts during collagen invasion assays, hydroxyproline levels were measured 
revealing a surprising reduction in collagen production by p19Arf -/- ALFs both in normal 
media and during LD. This data suggests that either collagen production is decreased in 
the absence of P19Arf or that the loss of p19Arf- in ALFs increases collagen degradation, 
but not collagen deposition in response to AAD (Figure 3.2D). Overall, these results 








    
 Loss of p19Arf increases autophagic flux in primary fibroblasts during LD 
Increased proliferation and long-term survival of p19Arf-null fibroblasts during LD 
implicates autophagy as a mechanism by which p19Arf-/- ALFs survive in the absence of 
the essential amino acid leucine. Previous studies have shown that in response to AAD, 
cells induce autophagy to recycle organelles and obtain nutrients required for survival. To 
investigate autophagic flux in WT and p19Arf-/- ALFs during LD, we examined expression 
of the p62 cargo receptor protein, and the dynamic processing of microtubule-associated 
proteins 1A/1B light chain 3B (LC3) from LC3-I to LC3-II by Western blot. We show 
increased p62 expression in p19Arf-null ALFs during prolonged AAD as compared to WT 
ALFs (Figure 3.3A). Similarly, we find an increase in LC3-II levels during AAD in p19Arf-
null ALFs at both baseline and in response to AAD (Figure 3.3B). Collectively these data 
suggest increased autophagy during LD in p19Arf null fibroblast promoting ALF survival. 
Treatment of ALFs with bafilomycin, a drug that raises the pH of the autophagolysosome 
to inhibit autophagy, showed an increase in LC3-II levels during leucine deprivation 
Figure 3.2: Loss of p19Arf enhances fibroblast activation during leucine deprivation 
(LD). A. Representative images and quantification of scratch closure by WT or p19Arf-/- 
fibroblasts in the presence of complete or LD media. Scratch closure rate was calculated at 
the indicated times relative to 0 hr.   Bar = 250µm, n= 3, * p< 0.05, ** p<0.01. B. 
Representative images and quantification of fibroblast transwell migration. WT or p19Arf -
/- fibroblasts were placed in serum-free media with or without LD in the top chamber of 
transwells and migrated toward complete serum-containing media in lower chamber. 
Migration was assessed after 24 hours by staining with crystal violet. Quantification of 
migrated cells per high powered field (hpf) is on right. Bar = 100µm, n=3, p<0.01. C. 
Representative images and quantification of collagen invasion assays. Fibroblast in serum-
free normal or leucine free media were placed in the top chamber of transwells coated with 
type 1 rat tail collagen bed and invaded through the collagen bed and migrate toward 
complete serum-containing media in lower chamber. Invasion was assessed after 72 hours 
by staining with crystal violet. Bar = 100µm, n=3. D. Quantification of hydroxyproline 
levels in conditioned media of WT and p19Arf -/- fibroblasts during collagen invasion 




confirming the induction of autophagy (Figure 3.3B). To determine the effect of autophagy 
on ALF survival, cells were subjected to LD and additionally treated with the autophagy 
inhibitors bafilomycin or hydroxychloroquine. We show that the survival benefit of p19Arf-
/- ALFs during LD is lost when autophagy is inhibited with either chloroquine (Figure 3.3C) 
or bafilomycin (Figure 3.3D) resulting in decreased ALF survival. These data confirm that 
p19Arf -/-ALF are dependent on autophagy to promote their survival during long-term LD 




Figure 3.3: Loss of p19Arf increases autophagy in primary fibroblasts during 
leucine deprivation (LD). A, B. Western blot analysis of autophagy markers (A) p62 
and (B) LC3-I to LC-3II conversion in WT and p19Arf-/- fibroblasts during LD for the 
indicated days. C, D. Fibroblast cell numbers in the presence of the autophagy 
inhibitors  (C) chloroquine [100nM] or (D) bafilomycin [1nM] during LD for the 






My data demonstrate that the increased proliferation of p19Arf -/- fibroblasts offer a 
survival advantage over WT fibroblasts in response to prolonged AAD. In support of this, 
I show that survival of p19Arf-/- ALFs during long-term LD is lost in the presence of the 
DNA synthesis inhibitor, mitomycin C indicating that increased proliferation is a critical 
mechanism for survival during LD. Our data also show increased migration of p19Arf-null 
fibroblasts during LD in scratch assays, through transwells and through a collagen bed 
suggesting that p19Arf-/- ALFs have the ability to promote tumor growth in the TME with 
limited nutrients.  
In response to nutrient deprivation, cells recycle existing cellular components to be 
used as nutrients to promote survival, a process known as autophagy. Cancer cells often 
use this mechanism for survival in the nutrient deprived TME, but increased autophagy 
has also been shown to inhibit tumor growth. We show here that autophagy is increased 
in p19Arf-null ALFs as compared to WT ALFs during LD as evidenced by the conversion 
of LC3-I to LC3-II and the degradation of p62. Interestingly, we find that p19Arf-/- fibroblasts 
at baseline contain higher levels of p62 and LC3-II that were even further upregulated 
when autophagy was inhibited, suggesting p19Arf-/- fibroblasts enhance autophagy to 
promote their survival. Using two well characterized autophagy inhibitors bafilomycin and 
hydroxychloroquine, I confirmed the importance of autophagy for survival of p19Arf-null 
fibroblasts during prolonged LD. The decreased survival of p19Arf-null ALFs during LD in 
the presence of bafilomycin or hydroxychloroquine confirms the necessity of autophagy to 
promote survival under nutrient deprivation conditions.  Further studies will be needed to 
42 
 
determine how p19Arf may directly or indirectly regulate autophagy to inhibit fibroblast 
survival under conditions of nutrient deprivation. Previous studies have shown that 
inhibition of autophagy in vivo slows tumor growth rates and inhibits tumor progression. It 
will be of interest to investigate whether restriction of an essential amino acid through diet 


























CHAPTER 4: Shear Stress and its Effect on the Tumor Microenvironment 
 
Introduction 
 In addition to stresses of the tumor microenvironment (TME) associated with the 
lack of resources due to a rapidly expanding tumor mass, there are other stresses 
induced by biophysical stimuli such as blood flow resulting in shear stress. Shear stress 
is defined as the measure of the force of friction from a fluid acting on a body in the path 
of that fluid103. The endothelial cell monolayer lining blood vessels throughout the body 
are directly exposed to the shear stress of blood flow. While physiologic shear stress is 
necessary for normal vascular function, aberrant or pathologic changes that disturb 
shear stress or cause oscillatory flow can activate endothelial cells altering their 
behavior104. Studies have shown that these changes can be associated with plaque 
deposits, atheroma formation and atherosclerotic disease103. Altered vascular flow 
affects the vascular endothelium at the cellular and molecular level changing gene 
expression, cytoskeletal rearrangement, and leukocyte adhesion among other things.  
These changes together with well-defined risk factors including obesity, smoking and 
hypertension lead to atherosclerosis, a chronic disease with plaque buildup in arteries 
restricting blood flow that can result in occlusion of the artery if the plaque ruptures105. 
Studies have shown that similar molecular pathways in endothelial cells play a role in the 
progression of both atherosclerosis and cancer105. In cancer, shear stress has been 
implicated as having both tumor promoting and suppressive abilities. Tumor cells are 
most likely to encounter shear stress during metastatic progression as they travel from 
the primary tumor to a distal metastatic organ site and are referred to as circulating 
tumor cells or CTCs.  Studies show that CTCs are exposed to variable levels of shear 
stress during metastatic progression that can promote its proliferation and extravasation 
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106–110. In contrast, increased shear stress has also been shown to reduce the number of 
viable CTCs in various tumor models110–112. Although pathologic stimuli can trigger 
increased shear stress, physiological methods such as aerobic exercise can also 
increase shear stress by increasing blood flow.   
      Shear stress induced by moderate exercise is an important mechanism to 
improve vascular function by stimulating activation of endothelial cells.  As tumor 
vasculature have poor endothelial function leading to leaky vessels, numerous studies 
have investigated the effects of normalizing tumor vasculature to improve drug delivery 
in cancer. As briefly mentioned in Chapter 1, the concept of tumor vascular 
normalization can be observed with the use of antiangiogenic treatments to restore the 
balance of pro- and antiangiogenic factors in the TME that leads to restoration of 
abnormal tumor vasculature towards a more normal state with improved tumor blood 
flow and increased oxygenation113. Tumor vascular normalization as a therapeutic 
strategy to increase drug delivery have generally utilized antiangiogenic treatments to 
promote normalization. These therapies lower the levels of pro-angiogenic factors such 
as VEGF, to attenuate the rapid growth and proliferation of endothelial cells leading to 
‘pruning’ of the excess endothelial cells causing vascular regression and a more normal 
vascular bed33,114. However, the use of antiangiogenic agents not only has a limited 
window for vascular normalization but is also accompanied by a number of adverse side 
effects115. A physiologic approach to increasing shear stress and activating endothelial 
cells is through aerobic exercise.  We previously published that tumor bearing-mice 
subjected to increased shear stress via treadmill running during chemotherapy showed 
normalization of tumor vasculature as evidenced by an increase in mature lumens that 
were more effective in perfusion and circulation of drugs to the tumor bed25. This study 
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also revealed the importance of the calcineurin - nuclear factor of activated T-cells 
(NFAT) - thrombospondin -1 (TSP-1) pathway in mediating vascular normalization116.   
More recently, another study demonstrated that TSP1 expression may serve as a 
biomarker of tumor vasculature normalization25,117. While these studies investigated the 
effects of chronic exercise on increasing chemotherapeutic efficacy, the effects of acute 
exercise on enhancing drug delivery and efficacy have not been investigated. 
       Aerobic exercise interventions can either be chronic, defined as repeated periods 
of short or longer term exercise, or acute, defined as a single bout of exercise. Based 
upon the effect of chronic exercise on tumor vascular normalization and increased 
chemotherapeutic efficacy, I hypothesized that a single session of acute aerobic 
exercise would not provide sufficient levels of shear stress to activate and remodel 
vasculature.  In our previous study, we showed that chronic exercise not only induced 
TSP-1 and endothelial nitric oxide synthase (eNOS) expression in the lungs but we also 
showed that TSP-1 expression was increased in the heart and spleen of these animals. 
These data confirm increased shear stress throughout the animal. My studies 
investigating the effect of acute exercise on tumor growth found that administration of 
drug immediately after a session of acute aerobic exercise, showed a modest 
suppression of tumor growth as compared to mice treated with drug alone.  
       Exercise induces adaptations in skeletal muscle through activation of the 
transcriptional co-activator peroxisome proliferator-activated receptor (PPAR) family of 
proteins with peroxisome proliferator-activated receptor gamma coactivator 1 alpha 
(PGC1- α) one of the best characterized family member118. PGC1- α functions in 
regulating mitochondrial biogenesis and oxidative metabolism and has been studied in a 
number of disease states including cancer. PGC1- α has been implicated across various 
46 
 
cancer types with increased expression in breast cancer associated with an increase in 
mitochondrial restoration and metastasis to the bone and lung118,119. It has also been 
shown to be necessary for drug resistance in colorectal cancer120. PGC1- α works in 
concert with the p53 tumor suppressor in promoting cancer cell survival through cell 
cycle arrest, which was lost when PGC1- α was deleted or the stress was prolonged121. 
Since PGC1-α is essential for exercise-induced upregulation of skeletal muscle VEGF, 
we were interested in exploring whether this factor effected exercise-induced tumor 
vascular normalization in our model system.  I hypothesized that increased PGC1- α 
expression in the skeletal muscles of exercised mice would increase VEGF levels 
systemically leading to more rapid tumor progression and metastasis to the lungs. 
Utilizing PGC1- α transgenic mice generated by Arany et al.122 with overexpression of 
PGC1- α in the skeletal muscles, I subjected mice to chronic aerobic exercise and 
observed no difference in the growth rates between control and transgenic mice. Using 
an experimental model of spontaneous lung metastases, I examined the incidence of 
lung metastasis in PGC1- α transgenic mice and littermate control mice after chronic 
exercise.  My data show no significant difference in lung metastases between exercised 
control versus transgenic mice. However, my studies do show that chronic aerobic 
exercise increased metastatic burden in both PGC1- α transgenic and control mice as 
compared to non-exercised transgenic or control mice suggesting that long-term 







Acute exercise increases chemotherapeutic efficacy attenuating tumor growth 
      As shown previously, chronic exercise in tumor bearing mice enhances 
chemotherapeutic efficacy through the normalization of tumor vasculature through a 
cellular mechanism that include activation of TSP-1 and the calcineurin-NFAT pathway 
in endothelial cells. Since the ability of cancer patients undergoing chemotherapy  to 
maintain a regular exercise program may be limited, we sought to determine if acute 
aerobic exercise or a single exercise training session would be sufficient to normalize 
tumor vasculature and increase the efficacy of chemotherapy. Utilizing a murine 
melanoma xenograft model in syngeneic wild-type (WT) mice, I inoculated mice with 
melanoma cells and when tumors reached 100 mm3 in volume, mice were treated with 
Doxorubicin (Dox).  The sedentary group were returned to their cages and the 
experimental group ran on a treadmill for one hour at a moderate intensity of VO2 as 
previously described25,123. These studies showed that acute exercise offered no 
increased efficacy of Dox treatment as tumors continued to grow even more rapidly in 





 One possible explanation for this increase in tumor growth after an acute exercise 
intervention in the presence of Dox was that the clearance of Dox occurred more rapidly 
upon the increase in blood flow from acute aerobic exercise. Next I examined the effect 
of Dox treatment within 15 minutes after completion of acute aerobic exercise in 
Figure 4.1: Acute exercise has no effect on tumor growth when drug is administered 
before exercise. A. Graph of melanoma (B16F10) tumor volume on indicated days. B16F10 
cells were injected into the flank of wild-type (WT) mice. Tumor volume was measured by 
caliper, N=8 (4 sedentary, 4 exercise) mice/cohort. Doxorubicin (Dox) was administered to 
both groups [2mg/kg] when tumor volume was ~100mm3 on Day 11, before the exercise 
group ran on the treadmill for 60 minutes at a rate of 12 m/min. B. Graph of B16F10 tumor 
volume when Dox was administered after running. WT mice receive B16F10 cells to their 
flank and were allowed to grow until the previously mentioned volume was obtained at 
which time exercise was performed and mice received Dox immediately after. C. Graph of 
pancreatic adenocarcinoma (PDAC) tumor volume when Dox is administered before and 
after running. WT mice were inoculated with syngeneic PDAC cells in their flank and 
received Gemcitabine (Gem) [15mg/kg] before or after acute exercise. Tumor volume was 




melanoma-bearing mice and found that tumor growth was inhibited when chemotherapy 
was administered after treadmill running as compared to the non-exercised melanoma-
bearing cohort (Figure 4.1B). However, when these studies were repeated utilizing a 
xenograft model of pancreatic ductal adenocarcinoma (PDAC), the administration of 
Gemcitabine (Gem) either before or after running had no effect on tumor growth (Figure 
4.1C). These data indicate that  chemotherapy administered after acute exercise may 
attenuate tumor growth only in specific cancer types. Further, I propose that the 
increased efficacy of Dox treatment after acute aerobic exercise may be due to the 
transient increase in shear stress permitting more efficient drug delivery to the tumor.  
 
PGC1- α has no effect on metastatic burden in the lungs after exercise 
      I next examined how chronic aerobic exercise would effect tumor progression in 
transgenic mice with PGC1- α overexpression124.  PGC1- α transgenic mice and 
littermate controls were inoculated with syngeneic Lewis lung carcinoma (LLC) cells into 
their flank and tumors were monitored for growth up to a volume of ~500mm3.  The 
growth rate of flank tumors were similar between transgenic and control mice  (Figure 
4.2A). Utilizing an experimental model of spontaneous lung metastases referred to as 
the injection/resection model125,  I resected flank tumors when they reached 500 mm3 
then both cohorts of mice (PGC1- α transgenic mice and littermate controls) were 
subjected to chronic aerobic exercise for two weeks at 12 meters per minute for 45 
minutes per day and five days a week prior to examining lungs for metastatic disease.  
After two weeks, mice were euthanized and lungs were harvested, fixed, paraffin 
embedded and sectioned. Lung sections were stained with hematoxylin and eosin to 
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identify metastatic lesions but revealed no difference in metastatic incidence, or size of 
metastatic lesions between the transgenic and control mice cohorts (Figure 4.2B). 
These data suggest that overexpression of PGC1-α in skeletal muscle  has no effect on 
tumor growth and metastasis and that chronic aerobic exercise had no impact on 
metastatic progression. 
 
Figure 4.2 Transgenic mice with overexpression of PGC1-α in skeletal muscle showed no 
difference in lung metastasis as compared to control mice metastasis after chronic 
aerobic exercise. A. Graph of Lewis lung carcinoma (LLC) flank tumor volume on indicated 
days. LLC cells were injected into the flank of WT and PGC1- α  transgenic mice. Tumor 
volume was measured by caliper. N=8 (4 sedentary, 4 exercise) mice/cohort. Tumors were 
resected when tumor volumes were ~500-800mm3. After three days of exercise training, , 
mice were subjected to chronic aerobic exercise 5 times a week at 12m/min for 45 minutes 
for two weeks at which point lungs were harvested and formalin fixed, paraffin embedded 
and sectioned. B. Representative images of lung sections from exercised mice stained with 
H&E. Bar = 50 pixels. Quantification of lung metastases per mouse and average size of lung 
metastases is shown below. Size of lung metastases was normalized to total lung area. N=27 




 My data reveal that the timing of chemotherapy delivery relative to a single bout 
of acute aerobic exercise is critical to inhibit tumor growth. I showed that tumor growth 
was attenuated only when Dox was administered immediately after acute aerobic 
exercise but not before acute exercise. It is possible that the delivery of Dox immediately 
after acute exercise may be more efficient due to the increased shear stress as a result 
of aerobic exercise. We have previously shown that when a bolus of Dox was 
administered before exercise, there was no difference in the amount of drug within the 
tumor between sedentary and exercised groups25. In this current study, I also examined 
the effect of transgenic overexpression of PGC1-α in muscles fibers on tumor growth 
and metastatic progression and found no effect on the growth of primary flank tumors as 
compared to control mice. Similarly, upon investigation of the effect of chronic aerobic 
exercise on metastatic progression in PGC1-α transgenic mice, I also found no 
significant difference in metastatic incidence or burden in exercised transgenic versus 
control mouse cohorts. However, metastatic burden was increased in exercised PGC1-α 
and exercised control mice as compared to their sedentary counterparts.   
      My data suggests an additional method to enhance delivery of chemotherapy 
immediately after an increase in shear stress. Further, our acute exercise regimen in 
mice would be roughly equivalent to brisk walking on an inclined treadmill for humans, a 
potentially feasible intervention for cancer patients.  It would be of interest to investigate 
the activation of the calcineurin-NFAT pathway by examining TSP-1 levels in response 
to acute exercise. While TSP-1 has been implicated in tumor vascular normalization and 
angiogenesis associated with chronic exercise, it may be altered in acute exercise or 
may be effected in response to Dox treatment. In addition to the calcineurin pathway and 
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its activation in response to changes in calcium levels as a consequence of VEGF-
mediated activation of endothelial cells, it would also be of interest to investigate the ISR 
pathway with particular interest in the PERK arm as changes in calcium levels also 
induces stress in the endoplasmic reticulum. Our studies investigating the role of PGC1-
α in tumor progression showed no significant effect of PGC1- α overexpression on 
tumorigenesis. However, the LLC tumor cells utilized in these mice are an aggressive 
and rapidly growing tumor line and more subtle effects of PGC1- α overexpression may 
be lost. Studies should be repeated with an alternate, slower growing tumor model and 
VEGF levels should be measured in tumor bearing-transgenic mice with and without 
chronic exercise to determine how VEGF levels are effected.  Another limitation to these 
studies is the fact that transgenic expression of PGC1- α was limited to type-II skeletal 
muscle fibers, it would be of interest to determine the effects on tumorigenesis if the 
PGC1-α transgene was conditionally activated in various cell types in the TME such as 
fibroblasts or endothelial cells or in distal organs that are common sites of metastasis 










CHAPTER 5: Conclusions and Future Directions  
 
Collectively, my thesis work has investigated the role of fibroblasts and 
endothelial cells in the tumor microenvironment (TME) in response to stress. My studies 
on fibroblasts demonstrate a role for the p19Arf tumor suppressor in fibroblasts in 
response to stresses of the TME. The loss of p19Arf in fibroblasts resulted in the 
increased activity and survival of primary lung fibroblasts during prolonged leucine 
deprivation (LD). Previous tumor studies have shown  that p19Arf is typically inactivated 
in a reciprocal manner to p53, however, studies have also shown p53-independent 
functions of p19Arf. While p19Arf-loss in mice leads to tumor development, this has been 
attributed primarily to impaired apoptosis while studies examining the role of p19Arf 
during development indicate that it plays a critical role in determining the balance 
between the rate of proliferation and apoptosis. Published studies investigating the loss 
of p19Arf in mouse embryonic fibroblasts (MEFs) show that these cells arrest in 
response to DNA damage and can also bypass senescence during aging. However, 
there are no studies that have investigated the loss of p19Arf in adult fibroblasts. My 
work indicates that loss of p19Arf in adult lung fibroblasts are resistant to amino acid 
deprivation (AAD) primarily due to increased proliferation of p19Arf-/- cells in the absence 
of p53-mediated activation of cell cycle checkpoints. This rapid proliferation of p19Arf-
null cells render these cells to be highly dependent on autophagy for survival during LD. 
This increase in fibroblast survival is tumor promoting in vivo as xenograft tumor models 
with wild-type (WT) p19Arf show increased tumor growth when transplanted into the 
flank of p19Arf -null mice, with loss of p19Arf in cells in the TME.  The novelty of my 
work has identified a role for p19Arf in the fibroblasts in the TME, in addition to its 
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upregulation in response to prolonged LD. Future directions include investigating the 
effects of p19Arf reintroduction into the stroma of the TME on tumor progression, and its 
role in inhibiting tumor progression in the context of p53 deficiency. Future studies 
should also include investigating the role of p14ARF in the TME of human cancers. 
Our  work on endothelial cells in the TME in response to shear stress has 
identified an alternative approach to tumor vascular normalization to increase the 
efficacy of chemotherapy. My studies suggest that a single bout of acute exercise may 
enhance chemotherapeutic efficacy if drugs are administered immediately after  a single 
session of aerobic exercise. My work demonstrates that attenuation in tumor growth 
rates occurs independent of tumor vasculature normalization and may be attributed to 
increased blood flow leading to more effective drug delivery to tumor beds.  Future 
studies investigating acute exercise should investigate the mechanism underlying how 
acute exercise before treatment slows tumor growth and the effect of acute exercise on 
activation of endothelial signaling pathways. 
My studies investigating  the effect of increased expression of peroxisome 
proliferator-activated receptor gamma coactivator 1 alpha (PGC1-α) in skeletal muscles 
showed no effect on tumor growth rates or metastatic progression when exposed to 
chronic exercise. These studies did show that chronic exercise increased metastatic 
progression in both wild-type and PGC1- α transgenic mice. Although this effect was not 
specific to overexpression of PGC1-α in skeletal muscles, future studies should 
investigate the role of PGC1-α overexpression in chemotherapeutic efficacy in other 




P19Arf is induced in fibroblasts in response to prolonged leucine deprivation  
My work shows that primary lung fibroblasts promote tumor growth in response 
to stresses of the TME. In this study we showed that the loss of p19Arf in adult lung 
fibroblasts enhanced tumor growth rates of sarcoma cells with WT p19Arf. A caveat to 
our mouse studies is that the loss of p19Arf  occurred in all cell types including immune 
cells such as macrophages. Other groups have shown that p19Arf  is required to prevent 
the transition of tumor suppressing type-I macrophages from becoming type-II, tumor 
promoting macrophages16. To address the effect of p19Arf loss specifically in fibroblasts, I 
utilized a 3D tumoroid model to limit the effect of tumor cell growth to primary lung 
fibroblasts. I generated 3D tumoroids by resuspending tumor cells and primary adult 
lung fibroblasts (ALFs) in Basement Membrane Extract (BME) that promote the 
formation of 3D-tumors with fibroblasts intercalating throughout the tumoroids.  Using 
this system, we showed that the loss of p19Arf in primary lung fibroblasts enhanced 
overall cell number that was further increased during LD. The increase in fibroblasts was 
associated with an increase in the number of actively proliferating α-SMA positive 
fibroblasts. While the deprivation of many essential amino acids is a common stress in 
the TME due to the rapid proliferation of tumor cells and overall nutrient deprivation in 
the TME, deprivation of the essential amino acid leucine was utilized in my experimental 
systems because of its potent effect on suppressing activation of the mTOR pathway 
during long-term LD and its inhibition of cancer cell survival53,126,127.   
My data reveal the novel finding that prolonged LD induced p19Arf expression 
and activation of the integrated stress response (ISR) pathway in fibroblasts. ISR 
activation was even further increased in the absence of p19Arf. Interestingly, I found 
elevated levels of phosphorylated eIF2-α at baseline in both WT and p19Arf -/- primary 
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fibroblasts. One potential explanation could be an artefact of tissue culture as fibroblasts 
are activated in tissue culture due to the stiffness of tissue culture plastic. Studies have 
shown increased fibroblast activation on stiff substrates with tissue culture plastic log-
fold stiffer than the extracellular matrix that fibroblasts are exposed to in vivo. This likely 
induced stress that was independent of AAD as the phosphorylation of eIF2-α is not 
exclusive to this stress128. Despite the baseline activation of the ISR in both WT and 
p19Arf-null fibroblasts, my studies focused on investigating the effect of LD on fibroblast 
activation and the role of p19Arf. 
In this study I show that the loss of p19Arf increased fibroblast function and 
survival during prolonged LD through increased proliferation that persisted during long-
term exposure to stress. I confirmed that the increased proliferation rate of p19Arf-null 
fibroblast was sufficient to maintain fibroblast survival during long-term LD as the 
increased proliferation rate was greater than the rate of apoptosis.  The treatment of 
p19Arf-null fibroblasts with mitomycin C (Mito C) to inhibit cellular proliferation revealed 
the dependence on increased proliferation of p19Arf-null fibroblasts for survival during 
long-term LD.  My data also found that increased fibroblast activation and function 
continued during prolonged LD. My data show an increase in collagen invasion by 
p19Arf-null fibroblasts although the number of cells that migrated entirely through the 
collagen bed was limited. Thus it is possible that the collagen gel prevented a nutrient 
gradient between cells in a serum-free chamber to the nutrient replenished media. It 
would be of interest to assess migration of p19Arf-null fibroblasts as compared to WT 
fibroblasts in the presence of tumor-conditioned media. I utilized a hydroxyproline assay 
to quantify collagen production by measuring hydroxyproline as a surrogate for collagen 
levels. I measured hydroxyproline in conditioned media from p19Arf-null and WT 
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fibroblasts during  invasion assays. However, fibroblast invasion in this context does not 
necessarily require an increased production of collagen but instead the degradation of 
collagen that is required for cells to migrate through the collagen bed. Thus my data 
indicate a decrease in hydroxyproline in conditioned media collected from p19Arf-null 
fibroblast invasion assays as compared to WT fibroblast invasion assay. It would be of 
interest to compare the rate of collagen deposition by treating fibroblasts with ascorbic 
acid, which forces the production of collagen by these cells39,129. The loss of p19Arf did 
not prevent apoptosis as measured by Annexin V during prolonged stress and I saw no 
differences in cell death between WT and p19Arf fibroblasts.  However, possible caveats 
to this data are that Annexin V is an early marker of apoptosis thus may not be an 
accurate indication of cell death in these populations and studies that have shown 
p19Arf  can induce cell death through autophagy independent of conventional apoptosis 
pathways84,85,102. 
Finally, my research investigated the role of autophagy as a survival mechanism 
by p19Arf-null fibroblasts to cope with prolonged LD. My data shows increased utilization 
and dependence on autophagy pathways to survive this long-term stress. At baseline, I 
show increased expression of the two autophagy markers p62 and LC3-II in p19Arf -/- 
fibroblasts when compared with WT fibroblasts that was maintained when exposed to 
prolonged LD. We also confirmed the necessity of autophagy through treatment with the 
autophagy inhibitor bafilomycin preventing lysosomal degradation of LC3-II revealing 
increased levels in p19Arf -/- fibroblasts at later time points indicating an increase in 
autophagic flux. Since bafilomycin treatment and probing for LC3-II expression is an 
efficient readout to indicate differences in autophagic flux, further studies should 
compare the amount of lysosomal LC3-II between groups through the labelling of LC3 
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with the mCherry-GFP marker. It would also be of interest to determine how p19Arf 
effects the expression of autophagy-related genes, such as ATG5, and how their 
deletion affects p19Arf -/- fibroblast survival during LD. Overall, our data indicate that the 
p19Arf tumor suppressor plays a role in the ISR pathway in primary fibroblasts to induce 
apoptosis during prolonged AAD to inhibit tumor progression. 
 
Future directions to identify the effects the loss of stromal p19Arf in vivo 
Moving forward, identifying the role of p19Arf and the ISR pathway in primary 
fibroblasts should be further investigated in vivo and in human cells in response to 
prolonged LD. While antibodies specific for mouse phosphorylated GCN2 (P-GCN2) are 
not available, a human-specific P-GCN2 antibody is commercially available and can be 
utilized on human fibroblasts that lack p14ARF that have been exposed to prolonged LD 
to compare activation of the ISR. It would also be of interest to compare levels of ATF4 
in the context of p19Arf -/- in response to stress in the TME. While most studies have 
studied ATF4 in the context of total protein expression, notably, nuclear ATF4 is the 
activated form of the protein and is an indication of its activity level in addition to mRNA 
levels130. In vivo, studies investigating the role p19Arf in the TME could be further 
explored by targeting p19Arf utilizing a tissue specific and inducible model to 
conditionally delete exon 2 of CDKN2A to specifically target p19Arf, and not p16Ink4131. 
While my thesis research has focused on the deprivation of leucine to primary 
fibroblasts, future studies would also investigate not only the other essential and 
conditional-essential amino acids, but also other stresses of the TME . Previous studies 
have shown that mice on a leucine-free diet can prevent the growth of breast cancer 
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xenograft53, thus it would be of interest to utilize a leucine-restricted diet for mice with a 
fibroblast specific deletion of p19Arf and determine its effects on tumor progression. 
Additionally, certain cancer types are more reliant on autophagy to promote tumor 
progression, thereby presenting a targetable, therapeutic window. Rangwala et al., have 
shown in phase I clinical trials that the utilization of hydroxychloroquine in combination 
with temozolomide, an anti-tumor alkylating agent, in a final dose cohort had a complete 
response and prolonged stable disease in melanoma patients132. Combining both a  
leucine restricted diet to create a greater dependence on autophagy, together with 
hydroxychloroquine and chemotherapy could enhance the effectiveness of cancer 
treatment.  
Future studies should also investigate the role of LD on activation of the mTOR 
pathway in fibroblasts of the TME and the role of the p19Arf tumor suppressor. While a 
previous study has shown that deletion of p19Arf is necessary to maintain activation of 
the mTOR pathway, it would be of interest to determine if p19Arf -/- fibroblasts are reliant 
on mTOR during stress to determine its potential as a therapeutic target95. In this current 
study, I primarily investigated overall induction of autophagy, but there are varying types 
of autophagy that occur within the cell. Other types of autophagy should also be 
investigated in greater depth considering the localization of the p19Arf isoform, smARF 
to the mitochondria. It would be of interest to determine if smARF played a role in the 
regulation and processing of mitophagy in cancer133–135 and to also determine if smARF 
plays a role in the process of mitochondrial fission and fusion, and whether it is altered in 
cancer136,137. Future studies should also investigate the recycling of the ribosome, 
ribophagy138–140, not only due to its role in cancer progression, but also because of 
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previous studies that have shown that one of the p53-independent functions of p19Arf 
including the regulation of ribosome biogenesis94,141.  
 
Acute exercise provides therapeutic window 
My work has shown an intervention by which a single session of aerobic exercise 
prior to the administration of the chemotherapy drug doxorubicin (Dox) was sufficient to 
attenuate melanoma growth rates in vivo. Interestingly, the administration of Dox prior to 
exercise had no effect on tumor growth and even showed an increase in tumor growth 
rates in mice when compared with their sedentary control counterparts. One reason for 
this may be the altered rate of metabolism when the drug is administered. Although our 
group has previously shown that the presence of Dox within the tumor is increased when 
mice were subject to a chronic exercise regimen, we also showed that Dox levels in the 
tumor bed were similar in the acute exercise group as compared with our sedentary 
group when Dox waa administered before exercise25. Further studies should also 
quantify the amount of Dox present within the tumor when administered after exercise. It 
is possible that the administration of drug prior to exercise led to increased clearance of 
Dox due to aerobic exercise-mediated increase in shear stress. Further studies should 
also measure the amount of drug in the liver to compare the clearance rate of Dox. The 
effects of acute aerobic exercise may be limited to specific drugs as our data did not see 
any difference when the drug Gemcitabine was administered either before or after 
exercise in our pancreatic cancer xenograft mouse model. Since the addition of exercise 
has been prescribed to enhance the quality of life of pancreatic cancer patients, we 
anticipated that exercise would alter pancreatic tumor growth142. However, the xenograft 
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model we utilized inoculated syngeneic murine pancreatic ductal adenocarcinoma cells 
into the flanks of WT mice and this tumor model has limited physiologically relevance to 
pancreatic cancer patients. Further studies should utilize one of the many well-
characterized genetically engineered mouse models of pancreatic cancer that closely 
recapitulates the clinical course of pancreatic cancer. Future studies should also 
investigate other tumor types to determine whether aerobic exercise could be beneficial. 
Additionally, to quantify the extent of shear stress-induced by acute exercise, endothelial 
nitric oxide synthase can be measured within the tumor and other tissues to determine 
how one session of acute exercise alters shear stress. 
 
Future directions to investigate chemotherapeutic efficacy during acute exercise 
Overall, this study has revealed acute aerobic exercise as an approach to 
potentially increase chemotherapy efficacy in vivo. Future studies will investigate 
activation of the calcineurin-NFAT pathway in endothelial cells to determine whether it is 
altered in response to acute exercise. Studies to determine the role of the unfolded 
protein response (UPR) in endothelial cells in response to increased shear stress would 
also be of great interest. As mentioned in Chapter 1, the UPR pathway is activated in 
response to changes in calcium levels and thapsigargin is a drug utilized to stress the 
endoplasmic reticulum (ER) by depleting calcium within cells. Readouts of the ER stress 
pathway include activation of PKR-like ER kinase (PERK) resulting in activation of the 
ISR pathway. One caveat to this could be the overlapping stresses inducing activation of 
the ISR as shear stress may also activate the heme-regulated eIF2α kinase (HRI) arm of 
the ISR pathway, and even conditional deletion of specific arms of the ISR may lead to 
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compensation as previous work has shown in the context of glutamine deprivation61. 
While anti-VEGF therapies and chronic exercise provide approaches for tumor vascular 
normalization and increasing tumor susceptibility to chemotherapy, perhaps the 
utilization of anti-VEGF therapy combined with acute exercise would also lead to 
increased chemotherapy efficacy. A caveat to this is that the increased amount of VEGF 
produced during exercise may be utilized by the tumor to promote growth. While this 
poses a potential conflict, utilizing low doses of anti-VEGF therapy to sequester VEGF 
combined with the increased circulation of the chemotherapeutic agent following acute 
exercise may provide similar benefits to chronic exercise.  
 
PGC1-α overexpression has no effect on tumor progression 
 In collaboration with the Arany lab, I have shown that peroxisome proliferator-
activated receptor gamma coactivator 1 alpha  (PGC1-α) overexpression in skeletal 
muscle has no effect on tumor growth rates or metastasis to the lungs of mice during 
exercise. In this model, the use of transgenic mice that overexpressed PGC1-α in 
skeletal muscles were compared to WT littermate control mice. Both cohorts of mice 
were inoculated with LLC tumor cells in their flanks with tumors resected after reaching 
500mm3 volume before initiating a chronic aerobic exercise program for two weeks. After 
this time period, mice were euthanized and examined for lung metastasis with no 
significant differences observed between experimental and control cohorts.  Future 
studies could alter the experimental model such that primary tumors were resected at 
smaller volumes or the use of slower growing tumor cells to ensure that tumors were still 
fully encapsulated at the time of resection.  While these experiments indicate that PGC1-
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α overexpression in skeletal muscles do not have an effect on tumor growth and 
metastasis, it would be of interest to compare the effects that overexpression of PGC1-α 
or other members of the PPAR family in cell types within the TME may have on tumor 
progression. 
 
Future directions to investigate the role of PGC1-α on chemotherapeutic efficacy 
While PGC1-α plays a critical role in cellular metabolism, it would be of interest to 
combine chemotherapeutic treatment of  tumor bearing mice with our single session 
acute exercise model to determine if the enhanced metabolism by these mice allows for 
increased clearance or penetrance of the drug within a tumor bed. Future studies 
comparing the effects of chronic or acute exercise on tumor growth and progression on 
the background of PGC1-α  overexpression will be of great interest.  
 
Clinical Implications 
 Expression levels of the p14ARF tumor suppressor has been suggested to serve 
as a marker of tumor progression in certain cancer models 143. In this study I’ve shown 
that AAD induces expression of p19Arf expression in primary lung fibroblasts. While 
p14ARF has been reported to function in either a tumor suppressing or promoting 
manner depending on the context and on the specific cancer type90,135, my work 
demonstrates that the p19Arf mouse homolog functions in fibroblasts in the TME to 
suppress tumor growth and that its loss or potential silencing in fibroblasts in the TME 
enhances tumor growth and fibroblast function and survival through autophagy. My 
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research suggests that the role of classic tumor suppressors should be further 
investigated in cellular populations in the TME.  I have also shown that acute exercise 
increases therapeutic efficacy when administered after exercise. This timing of drug 
delivery, before or after acute exercise, may have important clinical applications as a 
single bout of brisk walking on a treadmill prior to drug infusion may be a feasible 
intervention for cancer patients undergoing chemotherapy. Future studies could identify 
the cancer types that may be susceptible to acute exercise combined with chemotherapy 
and this approach could be tested in a clinical trial for patients willing and able to 
undertake acute exercise during chemotherapy.  
 In conclusion, my thesis work has shown a role for p19Arf in response to AAD in 
the TME that suppresses tumor growth through regulating fibroblast survival and 
activation. While the deletion of the P19Arf in the TME may not be physiologically 
relevant, it is possible that p14ARF expression may be epigenetically silenced and 
should be investigated.  My thesis research has also shown that a single session of 
acute aerobic exercise followed by chemotherapy treatment was sufficient to suppress 












CHAPTER 6: Material and Methods 
 
Primary lung fibroblasts isolation and culture 
Fibroblasts were cultured in DMEM-F12 + L-glutamine (Gibco) with 10% heat inactivated 
FBS, L-glutamine, and penicillin-streptomycin. To isolate primary lung fibroblasts, lungs 
from male and female 3-5-week-old mice were minced into small pieces with scissors 
then  dissociated in Hank’s buffered saline solution (HBSS) containing 5 mg/ml type II 
collagenase and 0.5 mg/ml deoxyribonuclease I (Worthington, #LS004176 and 
#LS002139) with shaking in Thermo Scientific MaxQ 5000 floor shaker at 37°C at 250 
rotations per minute for 45 minutes. Dissociated lungs were passed through 100μm and 
40μm filters to obtain a single cell suspension before resuspending in culture media and 
plating; fibroblasts were allowed to adhere for 1-2 hours at 37°C before non-adherent 
cells were washed off. Fibroblast identity was confirmed by immunostaining cultured 
cells for vimentin (goat, Santa Cruz #sc-7557, 1:100), CD45.2 (biotinylated mouse, BD 
Pharmingen #553771,1:100), and CD31 (rat, BD Pharmingen #553370, 1:100), followed 
by secondary antibody and streptavidin (Alexa Fluor 647 anti-goat IgG, Alexa Fluor 488 
anti-rat IgG, Alexa Fluor 555 streptavidin, all 1:100: Invitrogen #A-21447, A-11006, 
Thermo Fisher #S-21381 respectively); fibroblasts were >99% vimentin-positive, with 
<5% CD45+ contaminants and no CD31+ cells present. 
Western blot 
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA, 50 mmol/L Tris- 
HCl pH 8, 150 mmol/L NaCl, 1% Triton-X, 0.5% sodium deoxycholate, and 0.1% SDS) 
containing a protease inhibitor cocktail followed by centrifugation at 16,000 x g for 10 
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minutes, and supernatant was collected. Total protein content was quantified using BCA 
assay (Thermo Scientific). Protein loading of fibroblast lysates was normalized using the 
protein standard curve in the Bio-Rad Protein Assay Kit on samples diluted 1:10. Total 
protein from fibroblast lysates was analyzed by running samples in 4x Laemmli sample 
buffer (Bio-Rad) on a 4-12% gradient gel (GenScript). SDS-PAGE of lysates was 
performed using 5-20μg per sample at 100-110 V on 8, 10, or 12% gels depending on 
the size of the protein in question using the Bio-Rad Mini Protean Tetra Cell system. 
Proteins were transferred onto PVDF membranes at 100 V for 1 hour using the Bio-Rad 
Mini Trans-Blot system. Blots were blocked in 5% non-fat dry milk (LabScientific M-
0841) or 5% BSA (Roche, 03-116-956-001)in TBS-T (TBS + 0.1% Tween 20) and 
incubated with primary antibody diluted in blocking buffer at 4° C overnight (p19ARF : 
1:500, Novus Biologicals #NB200-174;; temperature (p19ARF (1:500; Novus Biologicals 
; #NB200-174), ATF4 (1:1000; Cell Signaling Technology; #11815), phospho-eIF2a 
(Ser51) (1:500; Cell Signaling Technology; #3597) total-eIF2a (1:1,000; Cell Signaling 
Technology; #9722), LC3B (1:1,000; Cell Signaling Technology; #2775S), p62 (1:1,000; 
Cell Signaling Technology; #5114), and NBR1 (1:1,000; Cell Signaling Technology; # 
9891). Anti-Beta tubulin (1: 1,000; # 2128) and a-actin (1:10,000, Sigma #A2668) was 
used as loading control. Blots were washed in TBS-T, and secondary antibodies 
(Horseradish peroxidase–conjugated anti-rabbit (1:2,000; Cell Signaling; #7074),  anti-
mouse (1:2,000; Cell Signaling Technology; #7076), or goat anti-rat (1:2,000; Cell 
Signaling Technology; #7077) were incubated in blocking buffer for 1-2 h at room 
temperature then washed with TBS-T. Bands were visualized using enhanced 
chemiluminescence reagent (100 mM Tris pH 8.6, 0.2 mM p-coumaric acid, 1.25 mM 




All animal experiments and subcutaneous (s.c.) xenografts were approved by the 
Institutional Animal Care and Use Committee at the University of Pennsylvania. Six wild-
type and 6 p19Arf -/- (3 male and 3 female mice per group) mice between 6 and 8 weeks 
old (purchased from  Jackson Laboratory) had 1.34 × 105 SKPY cells implanted s.c. in 
their flanks. Prior to injection, cells were grown in complete media (DMEM containing 
10% FBS). Cells were collected, resuspended in ice-cold serum-free DMEM for injection. 
For co-injection experiments,  a total of 3.75 x 105 cells (lung fibroblasts: LLC 1:1) were 
resuspended in ice-cold serum-free media and mixed with Basement Membrane Extract 
(Millipore Sigma, #3533-005-02) at a ratio 1:1. The final volume per injection for each 
experiment was 200μL. For acute exercise experiments, animals received 300,000 
melanoma (B16F10) or pancreatic ductal adenocarcinoma (PDAC 4462) to their 
subcutaneous flank and tumors were allowed to grow for 10 days. Mice received 
doxorubicin (2mg/kg) or gemcitabine (15mg/kg) chemotherapies for melanoma or 
pancreatic cancer models, respectively, before exercise on day 11 via intraperitoneal 
injections. Tumor bearing mice were exercised for 60 minutes at a pace of 12m/min 
using the Columbus Instruments Exer 3/6 Animal treadmill and were returned to housing 
to have tumor volume measured by calipers until the experimental endpoint. For PGC1-α 
transgenic mice tumor experiments, mice were provided by Dr. Zolt Arany (Perelman 
School of Medicine, University of Pennsylvania). PGC1-α transgenic and WT mice 
received 1x106 Lewis Lung Carcinoma (LLC) cells inoculated subcutaneously in their 
flank and tumor volume monitored using calipers. Tumors were surgically resected when 
they reach 500-800mm3 in volume.  After three days of recovery, mice were exercised 
for 45 minutes at a pace of 12m/min 5 times a week for two weeks. After the final 
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exercise session, mice were sacrificed, and lungs were inflated with formalin followed by 
paraffin embedding. Tumor volumes were recorded at the indicated timepoints using 
caliper measurements. The formula, V = (L)(W2) (π/6), was used to calculate tumor 
volume. Tumors were harvested and flash frozen in OCT compound for further analyses. 
Aerobic Exercise 
Mice were inoculated with 300,000 tumor cells in 200μl PBS subcutaneously in the flank. 
When tumors reached ~100 mm3 (4–7 days post injection) or the indicated volume, mice 
began treatment. For both B16F10 and PDAC tumor-bearing mice, acute exercise plus 
chemotherapy groups performed one session of 60 minutes of treadmill running once at 
12 m/min. For PDAC tumor-bearing mice, gemcitabine was delivered once by 
intraperitoneal (IP) injection before or after exercise. For B16F10 tumor- bearing mice, 
acute exercise plus doxorubicin groups performed one session of 60 minutes of treadmill 
running at 12 m/min. Mice received 2 mg/kg of doxorubicin by tail vein injection before or 
after exercise. After the final tumor measurement, mice were euthanized, and tumors 
were harvested and frozen in OCT. 
Tumoroid Assay 
Tumor cells were resuspended in Basement Membrane Extract (BME) and  layered onto 
a BME bed containing fibroblasts then exposed to complete or leucine deprived media. 
Three-dimensional tumoroids were imaged every two days for a week, with cell numbers 
and sizes were quantified. Tumoroids were collected and dissociated to acquire single 
cell suspension, concentrated via cytospin and stained for Ki67 and alpha smooth 
muscle actin (α-SMA) (1:100, Abcam, #56947). Alexa Fluor 488-donekyt-anti-sheep IgG 
(1:500, Novus Biologicals, #NBP1-75446), Alexa Fluor 594-goat-anti-rabbit IgG. 
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Fluorescent images were captured with a laser scanning confocal microscope. Confocal 
imaging was performed on a Leica TCS SP5 and processed using LAS AF software.  
GCN2 Inhibition 
Fibroblasts were treated with GCN2-IN-1 (MedChem Express HY-100877)  at a final 
concentration of 1µM in leucine deprived media overnight and cells harvested for 
analysis. 
Autophagy Inhibition 
Fibroblasts were exposed to leucine deprived media and exposed to Bafilomycin 
(Cayman Chemicals #11038) at a final concentration of 1nM in DMSO 2 hours before 
harvesting lysates and probing for LC3. In survival assays, fibroblasts were treated 
chloroquine (Sigma-Aldrich # C6628) at a final concentration of 100nM in leucine 
deprived media for the times indicated. 
Cell Cycle Arrest 
Fibroblasts were treated with Mitomycin C (Sigma Aldrich #M4287-2MG) at a final 
concentration of 4µg/mL in culture media and incubated for 6 hours before washing with 
cells replated in complete media. Cell cycle arrest was confirmed by the absence of EdU 
incorporation. 
Migration Assay 
Cells were grown to confluency in 12-well plates in triplicate. A scratch was generated 
with a 200-μL tip across each well and pictures taken at the starting timepoint, and at 2-4 
hour increments post-scratch until complete scratch closure. The percentage of area that 
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was “repaired” was measured using ImageJ software and plotted as the average of the 
triplicates with standard deviation (SD). Experiments were repeated three times. 
 
qRT-PCR  
Total RNA was processed and extracted with TrIzol reagent (Life Technologies, catalog 
no. 15596018) and Direct-zol RNA MicroPrep Kit (Zymo Research, #R2060). RT 
reaction was performed using High-Capacity RNA-to-cDNA Kit (Applied Biosystems, 
#4387406). qRT-PCR was then performed using SYBR Green Master Mix (Bimake, 
#B21202) and a ViiA7 Real-Time PCR Instrument (Applied Biosystems). SYBR probes 
were used to quantify the expression of p19Arf (Forward: 5’ AGA GGA TCT TGA GAA 
GAG GGC C 3’; Reverse: 5’ GCA GTT CGA ATC TGC ACC G 3’). Normalization was 
performed using the housekeeping genes 18S (Forward: 5’ 
CAATTACAGGGCCTCGAAAG 3’; Reverse: 5’AAACGGCTACCACATCCAAG). 
Samples were performed in triplicate with each experiment repeated twice. 
 
Hydroxyproline assay 
Media was collected from transwells during collagen invasion assays 48 hours post-
plating . Hydroxyproline levels were measured using the colorimetric Hydroxyproline 
Assay Kit (Sigma-Aldrich, #MAK0081KT) per manufacturer’s instructions to determine 




Cells were seeded onto sterile round coverslips (12 mm) on parafilm covered 10cm 
dishes at a density of 12,500 cells per coverslip. Cells were cultured in their respective 
media at 37°C, 5% CO2 for the times indicated. After treatment, EdU proliferation assays 
were performed with Click-iT EdU Alexa Fluor 594 Imaging Kit (Invitrogen, #C10339) 
according to manufacturer's instructions; fibroblasts were pulsed with 10 mM EdU for 
16–18 hours before fixation and staining. Coverslips were mounted face-down onto 
microscope slides using Vectashield anti-fade mounting medium (Vector Laboratories). 
Images were acquired with laser scanning microscope Zeiss LSM 510 with 63 × 
objective lens (Carl Zeiss AG). All microscope parameters were held constant across 
samples. At least nine different areas were imaged per sample. 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 8 software, using 
unpaired Student two-tailed t test. Data are presented as mean ± SEM of at least three 
independent experiments unless indicated that standard deviation was used. Statistical 















1. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 
582–598 (2016). 
2. Vicencio, J. M. et al. Senescence, apoptosis or autophagy? When a damaged cell 
must decide its path - A mini-review. Gerontology 54, 92–99 (2008). 
3. White, E. the role for autophagy in cancer (White, 2015).pdf. J. Clin. Invest. 125, 
42–46 (2015). 
4. B’Chir, W. et al. The eIF2α/ATF4 pathway is essential for stress-induced 
autophagy gene expression. Nucleic Acids Res. 41, 7683–7699 (2013). 
5. Ye, J. et al. The GCN2-ATF4 pathway is critical for tumour cell survival and 
proliferation in response to nutrient deprivation. EMBO J. 29, 2082–2096 (2010). 
6. Lines, G. C. et al. p14 ARF , PTEN Tumor Suppressor Genes in Human. Brain 
Pathol. 479, 469–479 (1999). 
7. Horiguchi, M. et al. Stress-regulated transcription factor ATF4 promotes 
neoplastic transformation by suppressing expression of the INK4a/ARF cell 
senescence factors. Cancer Res. 72, 395–401 (2012). 
8. Sharpless, N. E. & Sherr, C. J. Forging a signature of in vivo senescence. Nat. 
Rev. Cancer 15, 397–408 (2015). 
9. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA. Cancer J. Clin. 
70, 7–30 (2020). 
10. Paget, S. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF 
THE BREAST. Lancet 23, 571–573 (1889). 
11. Langley, R. R. & Fidler, I. J. The seed and soil hypothesis revisited - the role of 
tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128, 
2527–2535 (2012). 
12. Farhood, B., Najafi, M. & Mortezaee, K. CD8+ cytotoxic T lymphocytes in cancer 
immunotherapy: A review. J. Cell. Physiol. 234, 8509–8521 (2019). 
13. Ren, W. et al. Amino-acid transporters in T-cell activation and differentiation. Cell 
Death Dis. 8, 1–9 (2017). 
14. Scalise, M., Galluccio, M., Console, L. & Pochini, L. The Human SLC7A5 ( LAT1 
): The Intriguing Histidine / Large Neutral Amino Acid Transporter and Its 
Relevance to Human Health. 6, 1–12 (2018). 
15. Hayashi, K., Jutabha, P., Endou, H., Sagara, H. & Anzai, N. LAT1 Is a Critical 
Transporter of Essential Amino Acids for Immune Reactions in Activated Human T 
Cells. J. Immunol. 191, 4080–4085 (2013). 
73 
 
16. Través, P. G., Luque, A. & Hortelano, S. Macrophages, inflammation, and tumor 
suppressors: ARF, a new player in the game. Mediators Inflamm. 2012, (2012). 
17. Fairweather, D. L. & Cihakova, D. Alternatively activated macrophages in infection 
and autoimmunity. J. Autoimmun. 33, 222–230 (2009). 
18. Hanna, A. et al. Inhibition of Hedgehog signaling reprograms the dysfunctional 
immune microenvironment in breast cancer. Oncoimmunology 8, 1–16 (2019). 
19. Rodríguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived 
suppressor cells and tolerance in cancer: Mechanisms and therapeutic 
perspectives. Immunol. Rev. 222, 180–191 (2008). 
20. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated 
Melanoma. N. Engl. J. Med. 373, 23–34 (2015). 
21. Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to 
PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. 
Cancer Immunol. Res. 3, 399–411 (2015). 
22. Michiels, C. Endothelial cell functions. J. Cell. Physiol. 196, 430–443 (2003). 
23. Sasich, L. D. & Sukkari, S. R. The US FDAs withdrawal of the breast cancer 
indication for Avastin (bevacizumab). Saudi Pharm. J. 20, 381–385 (2012). 
24. Hida, K. et al. Tumor-associated endothelial cells with cytogenetic abnormalities. 
Cancer Res. 64, 8249–8255 (2004). 
25. Schadler, K. L. et al. Tumor vessel normalization after aerobic exercise enhances 
chemotherapeutic efficacy. Oncotarget 7, 65429–65440 (2016). 
26. Jaiprasart, P., Dogra, S., Neelakantan, D., Devapatla, B. & Woo, S. Identification 
of signature genes associated with therapeutic resistance to anti-VEGF therapy. 
Oncotarget 11, 99–114 (2020). 
27. Roberts, W. G. & Palade, G. E. Neovasculature induced by vascular endothelial 
growth factor is fenestrated. Cancer Res. 57, 765–772 (1997). 
28. Padera, T. P. et al. Cancer cells compress intratumour vessels. Nature 427, 695 
(2004). 
29. Dickson, P. V. et al. Bevacizumab-induced transient remodeling of the vasculature 
in neuroblastoma xenografts results in improved delivery and efficacy of 
systemically administered chemotherapy. Clin. Cancer Res. 13, 3942–3950 
(2007). 
30. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs 
brain tumor response to radiation. Cancer Cell 6, 553–563 (2004). 




32. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy : A new 
paradigm for combination therapy. Nat. Med. 8, 987–989 (2001). 
33. Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor 
receptor 2 blockade induces a pressure gradient across the vasculature and 
improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004). 
34. Chen, H., Yang, W. W., Wen, Q. T., Xu, L. & Chen, M. TGF-β-induced fibroblast 
activation protein expression, fibroblast activation protein expression increases 
the proliferation, adhesion, and migration of HO-8910PM. Exp. Mol. Pathol. 87, 
189–194 (2009). 
35. Dvorak, H. F. Tumors: Wounds that do not heal-redux. Cancer Immunol. Res. 3, 
1–11 (2015). 
36. Erdogan, B., Webb, D. J. & Daniel E Shumer, Natalie J Nokoff, N. P. S. Cancer-
associated fibroblasts modulate growth factor signaling and extracellular matrix 
remodeling to regulate tumor metastasis. Biochem. Soc. Trans. 176, 229–236 
(2017). 
37. Gaggioli, C. et al. Fibroblast-led collective invasion of carcinoma cells with 
differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9, 
1392–1400 (2007). 
38. Puré, E. & Blomberg, R. Pro-tumorigenic roles of fibroblast activation protein in 
cancer: back to the basics. Oncogene 37, 4343–4357 (2018). 
39. Lee, H.-O. et al. FAP-overexpressing fibroblasts produce an extracellular matrix 
that enhances invasive velocity and directionality of pancreatic cancer cells. 
Biomed Cent. Cancer 11, 254–263 (2011). 
40. Wikberg, M. L. et al. High intratumoral expression of fibroblast activation protein 
(FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 34, 
1013–1020 (2013). 
41. Santos, A. M., Jung, J., Aziz, N., Kissil, J. L. & Puré, E. Targeting fibroblast 
activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 
119, 3613–3625 (2009). 
42. Kraman, M. et al. Suppression of Antitumor. Science (80-. ). 330, 827–830 (2010). 
43. Wang, L. C. S. et al. Targeting fibroblast activation protein in tumor stroma with 
chimeric antigen receptor T cells can inhibit tumor growth and augment host 
immunity without severe toxicity. Cancer Immunol. Res. 2, 154–166 (2014). 
44. Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 
573, 430–433 (2019). 
45. Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G. & Amelio, I. The hypoxic 
tumour microenvironment. Oncogenesis 7, (2018). 
46. Ziello, J. E., Jovin, I. S. & Huang, Y. Hypoxia-Inducible Factor (HIF)-1 regulatory 
75 
 
pathway and its potential for therapeutic intervention in malignancy and ischemia. 
Yale J. Biol. Med. 80, 51–60 (2007). 
47. Wenger, R. H.  Cellular adaptation to hypoxia: O 2 -sensing protein hydroxylases, 
hypoxia-inducible transcription factors, and O 2 -regulated gene expression . 
FASEB J. 16, 1151–1162 (2002). 
48. Vander, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg 
Effect : Cell Proliferation Abu nant Scarce Ah Proliferative Starvation h Wowth No. 
324, 1029–1033 (2020). 
49. Yang, L. V. Tumor microenvironment and metabolism. Int. J. Mol. Sci. 18, 2–7 
(2017). 
50. Gentric, G., Mieulet, V. & Mechta-Grigoriou, F. Heterogeneity in Cancer 
Metabolism: New Concepts in an Old Field. Antioxidants Redox Signal. 26, 462–
485 (2017). 
51. Hu, J. wei, Sun, P., Zhang, D. xiang, Xiong, W. jun & Mi, J. Hexokinase 2 
regulates G1/S checkpoint through CDK2 in cancer-associated fibroblasts. Cell. 
Signal. 26, 2210–2216 (2014). 
52. Avagliano, A. et al. Metabolic Reprogramming of Cancer Associated Fibroblasts: 
The Slavery of Stromal Fibroblasts. Biomed Res. Int. 2018, (2018). 
53. Xiao, F. et al. Leucine deprivation inhibits proliferation and induces apoptosis of 
human breast cancer cells via fatty acid synthase. Oncotarget 7, 63679–63689 
(2016). 
54. Karolina Pakos-Zebrucka1, 2,†, Izabela Koryga1, 2,†, Katarzyna Mnich1, 2, Mila 
Ljujic1, 2, Afshin Samali1, 2 & Adrienne M Gorman1, 2. The integrated stress 
response. EMBO Rep. 17, 1374–1395 (2016). 
55. Han, A. P. et al. Heme-regulated eIF2α kinase (HRI) is required for translational 
regulation and survival of erythroid precursors in iron deficiency. EMBO J. 20, 
6909–6918 (2001). 
56. Chen, T. et al. Chemical genetics identify eIF2α kinase heme-regulated inhibitor 
as an anticancer target. Nat. Chem. Biol. 7, 610–616 (2011). 
57. White, M. C., Schroeder, R. D., Zhu, K., Xiong, K. & McConkey, D. J. HRI-
mediated translational repression reduces proteotoxicity and sensitivity to 
bortezomib in human pancreatic cancer cells. Oncogene 37, 4413–4427 (2018). 
58. Watanabe, T., Imamura, T. & Hiasa, Y. Roles of protein kinase R in cancer: 
Potential as a therapeutic target. Cancer Sci. 109, 919–925 (2018). 
59. Hiasa, Y. et al. Protein Kinase R Is Increased and Is Functional in Hepatitis C 




60. Rouschop, K. M. A. et al. The unfolded protein response protects human tumor 
cells during hypoxia through regulation of the autophagy genes MAP1LC3B and 
ATG5. J. Clin. Invest. 120, 127–141 (2010). 
61. Lehman, S. L., Ryeom, S. & Koumenis, C. Signaling through alternative 
Integrated Stress Response pathways compensates for GCN2 loss in a mouse 
model of soft tissue sarcoma. Sci. Rep. 5, (2015). 
62. Longchamp, A. et al. Amino Acid Restriction Triggers Angiogenesis via 
GCN2/ATF4 Regulation of VEGF and H2S Production. Cell 173, 117-129.e14 
(2018). 
63. Wang, Y. et al. Amino acid deprivation promotes tumor angiogenesis through the 
GCN2/ATF4 pathway. Neoplasia (United States) 15, 989–997 (2013). 
64. Robert, F. et al. Blocking UV-induced eIF2α phosphorylation with small molecule 
inhibitors of GCN2. Chem. Biol. Drug Des. 74, 57–67 (2009). 
65. Rashidi, A. et al. GCN2 is essential for CD8+ T cell survival and function in murine 
models of malignant glioma. Cancer Immunol. Immunother. 69, 81–94 (2020). 
66. Rivlin, N., Brosh, R., Oren, M. & Rotter, V. Mutations in the p53 tumor suppressor 
gene: Important milestones at the various steps of tumorigenesis. Genes and 
Cancer 2, 466–474 (2011). 
67. Sherr, C. J. Divorcing ARF and p53: An unsettled case. Nat. Rev. Cancer 6, 663–
673 (2006). 
68. Liu, J., Zhang, C., Hu, W. & Feng, Z. Tumor suppressor p53 and metabolism. J. 
Mol. Cell Biol. 11, 284–292 (2019). 
69. Vynnytska-Myronovska, B. O. et al. Arginine starvation in colorectal carcinoma 
cells: Sensing, impact on translation control and cell cycle distribution. Exp. Cell 
Res. 341, 67–74 (2016). 
70. Tang, X. et al. Comprehensive Profiling of Amino Acid Response Uncovers 
Unique Methionine-Deprived Response Dependent on Intact Creatine 
Biosynthesis. PLoS Genet. 11, 1–28 (2015). 
71. Qiu, W. et al. No evidence of clonal somatic genetic alterations in cancer-
associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 
40, 650–655 (2008). 
72. Hosein, A. N. et al. Breast carcinoma-associated fibroblasts rarely contain p53 
mutations or chromosomal aberrations. Cancer Res. 70, 5770–5777 (2010). 
73. Addadi, Y. et al. p53 status in stromal fibroblasts modulates tumor growth in an 
SDF1-dependent manner. Cancer Res. 70, 9650–9658 (2010). 
74. Arandkar, S. et al. Altered p53 functionality in cancer-associated fibroblasts 




75. Lehman, S. L. et al. Translational Upregulation of an Individual p21Cip1 Transcript 
Variant by GCN2 Regulates Cell Proliferation and Survival under Nutrient Stress. 
PLoS Genet. 11, 1–21 (2015). 
76. Westfall, M. D., Mays, D. J., Sniezek, J. C. & Pietenpol, J. A. The ΔNp63α 
Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has 
Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-
Derived Mutations. Mol. Cell. Biol. 23, 2264–2276 (2003). 
77. Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53-
dependent apoptosis and immortalization. Genes Dev. 12, 2424–2433 (1998). 
78. Zindy, F. et al. Arf tumor suppressor promoter monitors latent oncogenic signals in 
vivo. Proc. Natl. Acad. Sci. U. S. A. 100, 15930–15935 (2003). 
79. Cleveland, J. L. & Sherr, C. J. Antagonism of Myc functions by Arf. Cancer Cell 6, 
309–311 (2004). 
80. Khan, S. H., Moritsugu, J. & Wahl, G. M. Differential requirement for p19ARF in 
the p53-dependent arrest induced by DNA damage, microtubule disruption, and 
ribonucleotide depletion. Proc. Natl. Acad. Sci. U. S. A. 97, 3266–3271 (2000). 
81. Paliwal, S. et al. The alternative reading frame tumor suppressor antagonizes 
hypoxia-induced cancer cell migration via interaction with the COOH-terminal 
binding protein corepressor. Cancer Res. 67, 9322–9329 (2007). 
82. Tao, W. & Levine, A. J. P19ARF stabilizes p53 by blocking nucleo-cytoplasmic 
shuttling of Mdm2. Proc. Natl. Acad. Sci. U. S. A. 96, 6937–6941 (1999). 
83. Weber, J. D. et al. p53-independent functions of the p19 ARF tumor suppressor. 
2358–2365 (2000) doi:10.1101/gad.827300.ero. 
84. Eymin, B., Leduc, C., Coll, J. L., Brambilla, E. & Gazzeri, S. p14ARF induces G2 
arrest and apoptosis independently of p53 leading to regression of tumours 
established in nude mice. Oncogene 22, 1822–1835 (2003). 
85. Ozenne, P., Eymin, B., Brambilla, E. & Gazzeri, S. The ARF tumor suppressor: 
Structure, functions and status in cancer. Int. J. Cancer 127, 2239–2247 (2010). 
86. Randle, D. H., Zindy, F., Sherr, C. J. & Roussel, M. F. Differential effects of p19Arf 
and p16ink4a loss on senescence of murine bone marrow-derived preB cells and 
macrophages. Proc. Natl. Acad. Sci. U. S. A. 98, 9654–9659 (2001). 
87. Yetil, A. et al. p19ARF is a critical mediator of both cellular senescence and an 
innate immune response associated with MYC inactivation in mouse model of 
acute leukemia. Oncotarget 6, 3563–3577 (2015). 
88. White, E. & DiPaola, R. S. The double-edged sword of autophagy modulation in 
cancer. Clin. Cancer Res. 15, 5308–5316 (2009). 
89. Reef, S. et al. A Short Mitochondrial Form of p19ARF Induces Autophagy and 




90. Humbey, O. et al. The ARF tumor suppressor can promote the progression of 
some tumors. Cancer Res. 68, 9608–9613 (2009). 
91. Lowman, X. H. et al. HHS Public Access. 26, 3051–3060 (2019). 
92. Ying, S. & Khaperskyy, D. A. UV damage induces G3BP1-dependent stress 
granule formation that is not driven by translation arrest via mTOR inhibition. J. 
Cell Sci. jcs.248310 (2020) doi:10.1242/jcs.248310. 
93. Zimmerman, R. S. & Rosenberg, N. Changes in p19Arf Localization Accompany 
Apoptotic Crisis during Pre-B-Cell Transformation by Abelson Murine Leukemia 
Virus. J. Virol. 82, 8383–8391 (2008). 
94. Pelletier, J., Thomas, G. & Volarevic, S. Players and Therapeutic Avenues. Nat. 
Publ. Gr. 18, 51–63 (2017). 
95. Nakagawa, T. et al.  S6 Kinase- and β-TrCP2-Dependent Degradation of p19 Arf 
Is Required for Cell Proliferation . Mol. Cell. Biol. 35, 3517–3527 (2015). 
96. Wei, W., Hemmer, R. M. & Sedivy, J. M. Role of p14ARF in Replicative and 
Induced Senescence of Human Fibroblasts. Mol. Cell. Biol. 21, 6748–6757 
(2001). 
97. Hashimoto, M. et al. Elimination of p19ARF-expressing cells enhances pulmonary 
function in mice. JCI Insight 1, 1–15 (2016). 
98. Guo, F., Gao, Y., Wang, L. & Zheng, Y. P19Arf-p53 tumor suppressor pathway 
regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 
GTPase activities. J. Biol. Chem. 278, 14414–14419 (2003). 
99. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 
144, 646–674 (2011). 
100. Chen, Y., Paliwal, S., Draheim, K., Grossman, S. R. & Brian, C. p19Arf Inhibits the 
Invasion of Hepa tocellular Carcinoma Cells by Binding to CtBP. Cancer Res. 68, 
476–482 (2008). 
101. Stott, F. J. et al. The alternative product from the human CDKN2A locus, 
p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO 
J. 17, 5001–5014 (1998). 
102. Suzuki, H. et al. p19ARF-induced p53-independent apoptosis largely occurs 
through BAX. Biochem. Biophys. Res. Commun. 312, 1273–1277 (2003). 
103. Cunningham, K. S. & Gotlieb, A. I. The role of shear stress in the pathogenesis of 
atherosclerosis. Lab. Investig. 85, 9–23 (2005). 
104. Guo, D., Chien, S. & Shyy, J. Y. J. Regulation of endothelial cell cycle by laminar 
versus oscillatory flow: Distinct modes of interactions of AMP-activated protein 
kinase and akt pathways. Circ. Res. 100, 564–571 (2007). 
79 
 
105. Tapia-Vieyra, J. V., Delgado-Coello, B. & Mas-Oliva, J. Atherosclerosis and 
Cancer; A Resemblance with Far-reaching Implications. Arch. Med. Res. 48, 12–
26 (2017). 
106. Fan, R. et al. Circulatory shear flow alters the viability and proliferation of 
circulating colon cancer cells. Sci. Rep. 6, 1–8 (2016). 
107. Tremblay, P. L., Huot, J. & Auger, F. A. Mechanisms by which E-selectin 
regulates diapedesis of colon cancer cells under flow conditions. Cancer Res. 68, 
5167–5176 (2008). 
108. Lee, H. J. et al. Fluid shear stress activates YAP1 to promote cancer cell motility. 
Nat. Commun. 8, (2017). 
109. Novak, C. M., Horst, E. N., Taylor, C. C., Liu, C. Z. & Mehta, G. Fluid shear stress 
stimulates breast cancer cells to display invasive and chemoresistant phenotypes 
while upregulating PLAU in a 3D bioreactor. Biotechnol. Bioeng. 116, 3084–3097 
(2019). 
110. Huang, Q. et al. Fluid shear stress and tumor metastasis. Am. J. Cancer Res. 8, 
763–777 (2018). 
111. Regmi, S., Fu, A. & Luo, K. Q. High Shear Stresses under Exercise Condition 
Destroy Circulating Tumor Cells in a Microfluidic System. Sci. Rep. 7, 1–12 
(2017). 
112. Hyler, A. R. et al. Fluid shear stress impacts ovarian cancer cell viability, 
subcellular organization, and promotes genomic instability. PLoS One 13, 1–21 
(2018). 
113. Goel, S. et al. Normalization of the vasculature for treatment of cancer and other 
diseases. Physiol. Rev. 91, 1071–1121 (2011). 
114. Jain, R. K. Normalizing tumor microenvironment to treat cancer: Bench to bedside 
to biomarkers. J. Clin. Oncol. 31, 2205–2218 (2013). 
115. Jain, R. K. Antiangiogenesis Strategies Revisited: From Starving Tumors to 
Alleviating Hypoxia. Cancer Cell 26, 605–622 (2014). 
116. Oh-hora, M. & rao, A. The calcium/NFAT pathway: role in development and 
function of regulatory T cells. Microbes Infect. 11, 612–619 (2009). 
117. Yang, W. et al. TSP–1 as a novel biological marker of tumor vasculature 
normalization in colon carcinoma induced by Endostar. Oncol. Lett. 19, 2107–
2114 (2020). 
118. Bost, F. & Kaminski, L. The metabolic modulator PGC-1α in cancer. Am. J. 
Cancer Res. 9, 198–211 (2019). 
119. Andrzejewski, S. et al. PGC-1α Promotes Breast Cancer Metastasis and Confers 




120. Yun, C. W., Han, Y. S. & Lee, S. H. PGC-1α controls mitochondrial biogenesis in 
drug-resistant colorectal cancer cells by regulating endoplasmic reticulum stress. 
Int. J. Mol. Sci. 20, 1–14 (2019). 
121. Sen, N., Satija, Y. K. & Das, S. PGC-1α, a Key Modulator of p53, Promotes Cell 
Survival upon Metabolic Stress. Mol. Cell 44, 621–634 (2011). 
122. Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the 
transcriptional coactivator PGC-1α. Nature 451, 1008–1012 (2008). 
123. Mille-Hamard, L. et al. Skeletal muscle alterations and exercise performance 
decrease in erythropoietin-deficient mice: A comparative study. BMC Med. 
Genomics 5, 1–20 (2012). 
124. Lin, J. et al. Transcriptional co-activator PGC-1α drives the formation of slow-
twitch muscle fibres. Nature 418, 797–801 (2002). 
125. Kaplan, R. N., Rafii, S. & Lyden, D. Preparing the ‘soil’: The premetastatic niche. 
Cancer Res. 66, 11089–11093 (2006). 
126. Xu, D. et al. ATF4-Mediated Upregulation of REDD1 and Sestrin2 Suppresses 
mTORC1 Activity during Prolonged Leucine Deprivation. J. Nutr. 150, 1022–1030 
(2020). 
127. Sheen, J. H., Zoncu, R., Kim, D. & Sabatini, D. M. Defective Regulation of 
Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human 
Melanoma Cells In Vitro and In Vivo. Cancer Cell 19, 613–628 (2011). 
128. Skardal, A., Mack, D., Atala, A. & Sokern, S. Substrate elasticity controls cell 
proliferation, surface marker expression and motile phenotype in amniotic fluid-
derived stem cells. J. Mech. Behav. Biomed. Mater. 17, 307–316 (2013). 
129. Maione-Silva, L. et al. Ascorbic acid encapsulated into negatively charged 
liposomes exhibits increased skin permeation, retention and enhances collagen 
synthesis by fibroblasts. Sci. Rep. 9, 1–14 (2019). 
130. Zhang, C. et al. ATF4 is directly recruited by TLR4 signaling and positively 
regulates TLR4-trigged cytokine production in human monocytes. Cell. Mol. 
Immunol. 10, 84–94 (2013). 
131. Rawlins, E. L. & Perl, A. K. The a"MAZE"ing world of lung-specific transgenic 
mice. Am. J. Respir. Cell Mol. Biol. 46, 269–282 (2012). 
132. Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense 
temozolomide in patients with advanced solid tumors and melanoma. Autophagy 
10, 1369–1379 (2014). 
133. Budina-Kolomets, A., Hontz, R. D., Pimkina, J. & Murphy, M. E. A conserved 
domain in exon 2 coding for the human and murine ARF tumor suppressor protein 
is required for autophagy induction. Autophagy 9, 1553–1565 (2013). 
134. Pimkina, J., Humbey, O., Zilfou, J. T., Jarnik, M. & Murphy, M. E. ARF induces 
81 
 
autophagy by virtue of interaction with Bcl-xl. J. Biol. Chem. 284, 2803–2810 
(2009). 
135. Fontana, R., Ranieri, M., Mantia, G. La & Vivo, M. Dual role of the alternative 
reading frame ARF protein in cancer. Biomolecules 9, 1–21 (2019). 
136. Kashatus, D. The Role of Mitochondrial Dynamics in Ras- driven Cancers. 
Cancer.gov 10, 3000 (2019). 
137. Westermann, B. Mitochondrial fusion and fission in cell life and death. Nat. Rev. 
Mol. Cell Biol. 11, 872–884 (2010). 
138. Cebollero, E., Reggiori, F. & Kraft, C. Reticulophagy and ribophagy: Regulated 
degradation of protein production factories. Int. J. Cell Biol. 2012, (2012). 
139. Yen, W. L. & Klionsky, D. J. How to live long and prosper: Autophagy, 
mitochondria, and aging. Physiology 23, 248–262 (2008). 
140. Gwangwa, M. V., Joubert, A. M. & Visagie, M. H. Crosstalk between the Warburg 
effect, redox regulation and autophagy induction in tumourigenesis. Cell. Mol. 
Biol. Lett. 23, 1–19 (2018). 
141. Ulanet, D. B. & Hanahan, D. Loss of p19ArF facilitates the angiogenic switch and 
tumor initiation in a multi-stage cancer model via p53-dependent and independent 
mechanisms. PLoS One 5, (2010). 
142. Cormie, P. et al. Exercise as medicine in the management of pancreatic cancer: A 
case study. Med. Sci. Sports Exerc. 46, 664–670 (2014). 
143. Inoue, K. & Fry, E.  Aberrant expression of p14 ARF in human cancers: A new 
biomarker? . Tumor Microenviron. 1, 37 (2018). 
 
 
 
 
 
 
 
 
 
 
 
